

Please type a plus sign (+) inside this box ☐

11-01-00

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
This form is to be used to collect information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53 (b))

Attorney Docket No. LEX-0081-USA

First Inventor or Application Identifier Marie Harras et al.

Title Novel Human Transporter Proteins and Polynucleotide Encoding the Same

Express Mail label No. EL672756229US

PTO
10/31/00
13956 U.S. PTO

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1 ☐ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2 ☒ Specification (Total 25)
Pages
(Preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

3 ☐ Drawing(s) (35 U.S.C. 113) (Total 1)
Sheets

4 Oath or Declaration (Total 1)

a. ☒ Newly unexecuted (original or copy)

b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)

i ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

NOTE FOR ITEMS 1 & 3: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A
SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.29) EXCEPT IF
ONE FILED IN A PRIOR APPLICATION IS RELED UPON (37 C.F.R. § 1.26)

5. ☐ Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☒ Paper Copy (identical to computer copy)

c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))

8. ☐ 37 C.F.R. § 79(b) Statement (when there is an assignee) ☐ Power of Attorney

9. ☐ English Translation Document (if applicable)

10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

11. ☐ Preliminary Amendment

12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

13. ☒ Small Entity Statement ☐ Statement filed in prior application,
Status still proper and desired
(PTO/B02-12)

14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

15. ☐ Other: _____

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. _____

Prior application Information: Examiner _____

Group/Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label



or ☐ Correspondence address below

Name

24231

PATENT TRADEMARK OFFICE

Address

City

State

Zip Code

Country

Telephone

(281) 362-6554

Fax

(281) 364-0155

Name (Print/Type)

Lance K. Ishimoto

Registration No.

41866

Signature

Lance K. Ishimoto

Date

October 31, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c)) -- SMALL BUSINESS CONCERN**

Docket Number (Optional)
LEX-0081-USA

Applicant, Patentee, or Identifier: Marie Harras et al.

Application or Patent No.: _____

Filed or Issued: October 31, 2000

Title: Novel Human Transporter Proteins and Polynucleotides Encoding the Same

I hereby state that I am

- ☐ the owner of the small business concern identified below;
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Lexicon Genetics Incorporated

ADDRESS OF SMALL BUSINESS CONCERN 4000 Research Forest Drive, The Woodlands, TX 77381

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

- ☒ No such persons, concerns, or organizations exist.
☐ each such person, concern, or organization is listed below:

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Lance K. Ishimoto

TITLE OF PERSON IF OTHER THAN OWNER Vice President - Intellectual Property

ADDRESS OF PERSON SIGNING 4000 Research Forest Drive, The Woodlands, TX 77381

SIGNATURE 

Reg. No. 41,866

DATE October 31, 2000

**NOVEL HUMAN TRANSPORTER PROTEINS AND
POLYNUCLEOTIDES ENCODING THE SAME**

5 The present application claims the benefit of U.S.
Provisional Application Number 60/163,018 which was filed on
November 2, 1999 and is herein incorporated by reference in its
entirety.

1. INTRODUCTION

10 The present invention relates to the discovery,
identification, and characterization of novel human
polynucleotides encoding proteins that share sequence similarity
with mammalian transporter proteins. The invention encompasses
the described polynucleotides, host cell expression systems, the
15 encoded proteins, fusion proteins, polypeptides and peptides,
antibodies to the encoded proteins and peptides, and genetically
engineered animals that either lack or over express the disclosed
genes, antagonists and agonists of the proteins, and other
compounds that modulate the expression or activity of the proteins
20 encoded by the disclosed genes that can be used for diagnosis,
drug screening, clinical trial monitoring, the treatment of
diseases and disorders, or otherwise contributing to the quality
of life.

2. BACKGROUND OF THE INVENTION

25 Transporter proteins are integral membrane proteins that
mediate or facilitate the passage of materials across the lipid
bilayer. Given that the transport of materials across the
membrane can play an important physiological role, transporter
proteins are good drug targets. Additionally, one of the
30 mechanisms of drug resistance involves diseased cells using
cellular transporter systems to export chemotherapeutic agents
from the cell. Such mechanisms are particularly relevant to cells
manifesting resistance to a multiplicity of drugs.

3. SUMMARY OF THE INVENTION

The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with mammalian multi-drug resistance (MDR) proteins and cellular transporters.

The novel human nucleic acid sequences described herein, encode alternative proteins/open reading frames (ORFs) of 659, 705, 1,063, 496, 542, 900, 978, 1,024, 1,382, 815, 861, 1,219, and amino acids in length (see SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 respectively).

The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP genes (e.g., expression constructs that place the described gene under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or "knock-outs" (which can be conditional) that do not express a functional NHP. A knockout ES cell line has been produced that contains a gene trap mutation in the murine ortholog of the described gene.

Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing provides the sequences of the described NHP ORFs that encode the described NHP amino acid sequences. SEQ ID NO:25 describes a NHP ORF as well as flanking 5' and 3'

5 sequences.

5. DETAILED DESCRIPTION OF THE INVENTION

The NHPs, described for the first time herein, are novel proteins that are expressed in, *inter alia*, human cell lines, predominantly in human mammary gland, as well as human fetal liver, prostate, testis, and gene trapped human cells.

The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described genes, including the specifically described NHPs, and the NHP products; (b) nucleotides that encode one or more portions of the NHPs that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of an NHP, or one of its domains (e.g., a receptor or ligand binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide; or (e) therapeutic or diagnostic derivatives of the described polynucleotides such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs comprising a sequence first disclosed in

the Sequence Listing. As discussed above, the present invention includes: (a) the human DNA sequences presented in the Sequence Listing (and vectors comprising the same) and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF) that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, *e.g.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. *et al.*, eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of a DNA sequence that encodes and expresses an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, *e.g.*, washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, *supra*), yet still encodes a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species and mutant NHPs whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Patent No. 5,837,458). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

Additionally contemplated are polynucleotides encoding NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using standard default settings).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP gene nucleotide sequences. Such hybridization conditions may be highly stringent or less highly
5 stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that
10 incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc..

15 Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a micro array or high-throughput "chip" format). Additionally, a series of the described NHP oligonucleotide sequences, or the complements
20 thereof, can be used to represent all or a portion of the described NHP sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length can partially overlap each other and/or the NHP sequence may be represented using oligonucleotides that do not
25 overlap. Accordingly, the described NHP polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 18, and preferably about 25, nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences
30 may begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation.

For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic

5 acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, 10 such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety which is selected from the group including but not limited to

15 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 20 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 25 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. 30

The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier *et al.*, 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, FEBS Lett. 215:327-330).

Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

Oligonucleotides of the invention can be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein *et al.* (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and

Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately
5 stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms),
10 determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g.,
15 splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or "wobble" oligonucleotide primer pools designed on
20 the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express an allele of a NHP gene.

25 The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as
30 a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see e.g., Sambrook et al., 1989, *supra*.

A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, obesity, high blood pressure,

connective tissue disorders, infertility, etc.), or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to
5 identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to sequence analysis according to methods well known to those skilled in the art.

Additionally, an expression library can be constructed
10 utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening
15 techniques in conjunction with antibodies raised against a normal NHP product, as described below. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

Additionally, screening can be accomplished by screening with
20 labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to
25 cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

The invention also encompasses (a) DNA vectors that contain
30 any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding

sequences (for example, baculo virus as described in U.S. Patent No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that
5 directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells that express an endogenous NHP gene under the control of an exogenously introduced regulatory element (*i.e.*, gene activation). As used herein, regulatory elements include, but are not limited to,
10 inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the human cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements
15 (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase
20 (PGK), the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs
25 that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (*e.g.*, expression constructs in which NHP coding sequences are operatively associated with expression
30 control elements such as promoters, promoter/enhancers, etc.).

The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for

the diagnosis of disease. The NHP proteins or peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for an NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

Finally, the NHP products can be used as therapeutics. For example, soluble derivatives such as NHP peptides/domains corresponding the NHPs, NHP fusion protein products (especially NHP-Ig fusion proteins, i.e., fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics the NHP could activate or effectively antagonize the endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHPs, mutant NHPs, as well as antisense and ribozyme molecules can also be used in "gene therapy" approaches for the modulation of NHP expression. Thus, the invention also

encompasses pharmaceutical formulations and methods for treating biological disorders.

Various aspects of the invention are described in greater detail in the subsections below.

5

5.1 THE NHP SEQUENCES

The cDNA sequences and the corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence Listing. The NHP nucleotides were obtained from clustered human
10 gene trapped sequences, ESTs, and human testis and mammary gland cDNA libraries (Edge Biosystems, Gaithersburg, MD). The described sequences can also incorporate several coding region single nucleotide polymorphisms (cSNPs). The first polymorphism is a A to G transition at position 704 of, for example, SED ID NO: 23,
15 which results in a corresponding change of gln to an arg at, for example, position 235 of SEQ ID NO:24; the second can occur at position 2184 of, for example, SEQ ID NO:23 that changes a gln to a his at position 728 of, for example, SEQ ID NO:24; and the third cSNP involves a silent T to C transition at position 2,436 of, for
20 example, SEQ ID NO:23.

Similar MDR encoding sequences, uses, and applications that are germane to the described NHPs, are described in U.S. Patents Nos. 5,198,344 and 5,866,699 which are herein incorporated by reference in their entirety.

25

5.2 NHPS AND NHP POLYPEPTIDES

NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include but are not
30 limited to the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the

therapeutic treatment of mental, biological, or medical disorders and diseases. Given the similarity information and expression data, the described NHPs can be targeted (by drugs, oligos, antibodies, etc.) in order to treat disease, or to therapeutically
5 augment the efficacy of, for example, chemotherapeutic agents used in the treatment of breast or prostate cancer.

The Sequence Listing discloses the amino acid sequences encoded by the described NHP genes. The NHPs typically display have initiator methionines in DNA sequence contexts consistent
10 with a translation initiation site.

The NHP amino acid sequences of the invention include the amino acid sequence presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention.
15 In fact, any NHP protein encoded by the NHP nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and,
20 accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid "triplet" codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together
25 with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell et al. eds., Scientific American Books, New York, NY, herein incorporated by reference) are generically representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino
30 acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria,

including, but not limited to, the ability to bind and cleave a substrate of a NHP, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where, as in the present instance, the NHP peptide or polypeptide is thought to be membrane protein, the hydrophobic regions of the protein can be excised and the resulting soluble peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional equivalent, *in situ*. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of

the NHP, but to assess biological activity, e.g., in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the *lacZ* coding region so that a fusion protein is produced; pIN vectors (Inouye &

Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NHP gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed (e.g., see Smith et al., 1983, J. Virol. 46:584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan &

Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to,

CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which

5 stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows
15 cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of
20 compounds that affect the endogenous activity of the NHP product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc.

25 Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk⁻, hgp⁻ or ap⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to
30 methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers

resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, 1981, *J. Mol. Biol.* 150:1); and hygro, which confers resistance to hygromycin (Santerre, *et al.*, 1984, *Gene* 30:147).

Alternatively, any fusion protein can be readily purified by
5 utilizing an antibody specific for the fusion protein being
expressed. For example, a system described by Janknecht *et al.*
allows for the ready purification of non-denatured fusion proteins
expressed in human cell lines (Janknecht, *et al.*, 1991, *Proc.*
Natl. Acad. Sci. USA 88:8972-8976). In this system, the gene of
10 interest is subcloned into a vaccinia recombination plasmid such
that the gene's open reading frame is translationally fused to an
amino-terminal tag consisting of six histidine residues. Extracts
from cells infected with recombinant vaccinia virus are loaded
onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged
15 proteins are selectively eluted with imidazole-containing buffers.

5.3 ANTIBODIES TO NHP PRODUCTS

Antibodies that specifically recognize one or more epitopes
of a NHP, or epitopes of conserved variants of a NHP, or peptide
20 fragments of a NHP are also encompassed by the invention. Such
antibodies include but are not limited to polyclonal antibodies,
monoclonal antibodies (mAbs), humanized or chimeric antibodies,
single chain antibodies, Fab fragments, F(ab')₂ fragments,
fragments produced by a Fab expression library, anti-idiotypic
25 (anti-Id) antibodies, and epitope-binding fragments of any of the
above.

The antibodies of the invention may be used, for example, in
the detection of NHP in a biological sample and may, therefore, be
utilized as part of a diagnostic or prognostic technique whereby
30 patients may be tested for abnormal amounts of NHP. Such
antibodies may also be utilized in conjunction with, for example,
compound screening schemes for the evaluation of the effect of
test compounds on expression and/or activity of a NHP gene

product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method
5 for the inhibition of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals may be immunized by injection with the NHP, an NHP peptide (e.g., one
10 corresponding the a functional domain of an NHP), truncated NHP polypeptides (NHP in which one or more domains have been deleted), functional equivalents of the NHP or mutated variant of the NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various
15 adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin,
20 pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin,
25 tetanus toxoid, diptheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of
30 antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975,

Nature 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal

- 5 Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the
- 10 presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes

15 from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived

20 from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety.

- 25 Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against NHP gene
- 30 products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the $F(ab')_2$ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a NHP can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that "mimic" the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP mediated pathway.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents, and patent applications are herein incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in the NHP gene described in SEQ ID NO: 23.

2. An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 24; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 23 or the complement thereof.

3. An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 2; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 1 or the complement thereof.

4. An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 48; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 47 or the complement thereof.

ABSTRACT

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
223

PATENT APPLICATION

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

ATTORNEY DOCKET NO. LEX-0081-USA

As a below named inventor, I hereby declare that:

My residence/post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Novel Human Transporter Proteins and Polynucleotides Encoding the Same

the specification of which is attached hereto unless the following box is checked:

() was filed on _____ as US Application Serial No. or PCT International Application
Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

Foreign Application(s) and/or Claim of Foreign Priority

I hereby claim foreign priority benefits under Title 35, United States Code Section 119 of any foreign application(s) for patent or inventor(s) certificate listed below and have also identified below any foreign application for patent or inventor(s) certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE FILED	PRIORITY CLAIMED UNDER 35 U.S.C. 119
			YES: _____ NO: _____
			YES: _____ NO: _____

Provisional Application

I hereby claim the benefit under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below:

APPLICATION SERIAL NUMBER	FILING DATE
60/163,018	11/2/1999

U.S. Priority Claim

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NUMBER	FILING DATE	STATUS(patented/pending/abandoned)

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) listed below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Lance K. Ishimoto, Reg. No. 41866

Send Correspondence to:

Lance K. Ishimoto
Lexicon Genetics Incorporated
4000 Research Forest Drive
The Woodlands, TX 77381

Direct Telephone Calls To:

Lance K. Ishimoto
(281) 362-6554

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION (continued)

ATTORNEY DOCKET NO. LEX-0081-USA

Full Name of Inventor: Marie Harras

Citizenship: Republic of Ireland

Residence: 28717 Driftwood Lane, Spring, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Gregory Donoho

Citizenship: USA

Residence: 41 Fallenstone Dr., The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: C. Alexander Turner, Jr.

Citizenship: USA

Residence: 67 Winter Wheat Place, The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Michael C. Nehls

Citizenship: Germany

Residence: Paul-Keller-Strasse 6, Stockdorf, Germany 82131

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Glenn Friedrich

Citizenship: Canada

Residence: c/o Breland & Breland, Houston, TX 77004

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Brian Zambrowicz

Citizenship: USA

Residence: 18 Firethorne Place, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature

Date

DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION (continued)

ATTORNEY DOCKET NO. LEX-0081-USA

Full Name of Inventor: Arthur T. Sands

Citizenship: USA

Residence: 163 Bristol Bend Circle, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature

Date

SEQUENCE LISTING

<110> Harras, Marie
Donoho, Gregory
Turner, C. Alexander Jr.
Nehls, Michael
Friedrich, Glenn
Zambrowicz, Brian
Sands, Arthur T.

<120> Novel Human Transporter Proteins and
Polynucleotides Encoding the Same

<130> LEX-0081-USA

<150> US 60/163,018

<151> 1999-11-02

<160> 25

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1977

<212> DNA

<213> homo sapiens

<400> 1

atgacaaaga	tggtctgtga	ggctcagcat	cacacatctg	aggtcagcga	ccagcgcatc	60
cgtgtgacca	gtgaagtctt	cacttgcatt	aagctgatta	aaatgtacac	atgggagaaa	120
ccatttgcga	aaatcattga	agacctaaga	aggaaggaaa	ggaagctatt	ggagagtgct	180
gggcttgtcc	agagccctgac	aagtataacc	ttgttcatca	tccccacagt	ggccacagcg	240
gtctgggttc	tcatccacac	atccttaaag	ctgaatacct	cagcgctcat	ggccttcagc	300
atgtctggct	ccttgaatct	ccttcggctg	tcagtggtct	ttgtgcctat	tcagtgctaaa	360
ggcttcagca	attccaaagt	tgcatgtgat	aggttcaaga	agtttttctt	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaga	ctctgggtct	tgaggaggcc	480
acctgtgcat	ggcaacagac	ctgtcccggt	atcgtcaatg	gggcactgga	gctggagagg	540
aacgggcatg	cttctgaggg	gatgaccagg	cctagagatg	ccctcggggc	agaggaaaga	600
gggaacagcc	tgggccacga	gttgacacag	atcaacctgg	tggtgtccaa	ggggatgatg	660
ttaggggtct	gcggcaacac	ggggagtggt	aagagcagcc	tggtgtcagc	catcctggag	720
gagatgcact	tgctcgaggg	ctcgggtggg	gtgcagggaa	gcctggccta	tgctccccag	780
caggccttga	tgctcagcgg	gaacatcagg	gagaacatcc	tcattgggag	cgcatatgac	840
aaggcccgat	acctccaggt	gctccactgc	tgctccctga	atcgggacct	ggaactctct	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctctgg	ggggcagaaa	960
cagaggatca	gcctggcccg	cgccgtctat	tcggaccgtc	agatctacct	gctggagcac	1020
cccctgtctg	ctgtggagcg	ccacgtgggg	aagcacattt	ttgaggagtg	cattaaagaag	1080
acactcaggg	gggaagacgt	gcctctgggt	accacacagc	tgcaagtact	agaattttgt	1140
ggccagatca	ttttgttga	aaatgggaaa	atctgtgaaa	atggaaacta	cagttagtta	1200
atgcagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgacacaaga	agccactctg	1260
gacatgtttg	aggacacagc	aaagatagca	gagaagccaa	aggttagaaa	tcaggtctct	1320
gccacctccc	tggaagagtc	tctcaacgga	aatgctgtgc	cggagcatca	gctcacacag	1380
gaggaggaga	tggaagaagg	ctccttgagt	tggaggggtc	accaccacta	catccaggca	1440
gctggagggt	acatgtgtct	ttgcataatt	ttcttctctg	tggtgtgtat	cgtctctcta	1500
acgatcttca	gcttctgggt	gatgagctac	tggtttggagc	agggctcggg	gaccaatagc	1560

agccgagaga gcaatggaac catggcagac ctgggcaaca ttgcagacaa tcttcaactg 1620
 tcttcttacc agctgggtgta cgggctcaac gcctgtctcc tcatctgtgt ggggggtctgc 1680
 tcttcaggga ttttcaccaa ggtcacgagg aaggcatcca cggccctgca caacaagctc 1740
 ttcaacaagg ttttcgctg ccccatgagt ttctttgaca ccatccaat aggcgggctt 1800
 ttgaactgct tcgcaggga cttggaacag ctggaccagc tcttgcccat cttttcagag 1860
 cagttctcgg tctgtctctt aatggtgata gccgtctctg tgattgtcag tgtgtctgtc 1920
 ccataatatc tgtaaatggg agccataatc atggttattt gcttcattta ttatatg 1977

<210> 2

<211> 659

<212> PRT

<213> homo sapiens

<400> 2

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10						15	
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
			50			55					60				
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65					70					75				80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
					85					90				95	
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100				105						110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
			115				120					125			
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
			130			135						140			
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
145					150					155				160	
Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu
			165						170					175	
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg
			180					185					190		
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu
			195				200					205			
His	Lys	Ile	Asn	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys
			210			215					220				
Gly	Asn	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu
225					230					235				240	
Glu	Met	His	Leu	Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala
			245						250					255	
Tyr	Val	Pro	Gln	Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn
			260				265						270		
Ile	Leu	Met	Gly	Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu
			275				280					285			
His	Cys	Cys	Ser	Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp
			290			295					300				
Met	Thr	Glu	Ile	Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys
305				310					315					320	
Gln	Arg	Ile	Ser	Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr
			325					330					335		

Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His
 340 345 350
 Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val
 355 360 365
 Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile
 370 375 380
 Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu
 385 390 395 400
 Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys
 405 410 415
 Glu Ala Thr Ser Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys
 420 425 430
 Pro Lys Val Glu Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu
 435 440 445
 Asn Gly Asn Ala Val Pro Glu His Gln Leu Thr Gln Glu Glu Met
 450 455 460
 Glu Glu Gly Ser Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala
 465 470 475 480
 Ala Gly Gly Tyr Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu
 485 490 495
 Ile Val Phe Leu Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu
 500 505 510
 Glu Gln Gly Ser Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met
 515 520 525
 Ala Asp Leu Gly Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln
 530 535 540
 Leu Val Tyr Gly Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys
 545 550 555 560
 Ser Ser Gly Ile Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu
 565 570 575
 His Asn Lys Leu Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe
 580 585 590
 Asp Thr Ile Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu
 595 600 605
 Glu Gln Leu Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val
 610 615 620
 Leu Ser Leu Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser
 625 630 635 640
 Pro Tyr Ile Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile
 645 650 655
 Tyr Tyr Met

<210> 3
 <211> 2115
 <212> DNA
 <213> homo sapiens

<400> 3
 atgacaagaa tggctgtgaa ggctcagcat cacacatctg aggtcagcga ccagcgcatc 60
 cgtgtgacca gtgaagtctt cacttgcatt aagctgatta aaatgtacac atggagagaaa 120
 ccatttgcga aaatcattga agacctaaga aggaaggaaa ggaagctatt ggagaagtgc 180
 gggcttgtcc agagcctgac aagtataacc ttgttcatala tcccacagt gccacagcg 240
 gtctgggttc tcattccacac atccttaaaag ctgaaactca cagcgctcaat ggccttcagc 300
 atgtctggcct ccttgaatct ccttcggctg tcagtggtct ttgtgcctat tgcagtcaaa 360
 ggtctcacga attccaaatc tgcagtgatg aggttcaaga agtttttctt ccaggagagc 420

cctgttttct	atgtccagac	attacaagac	cccagcaag	ctctggttct	tgaggaggcc	480
accttgtcat	ggcaacagac	ctgtcccg	atcgtaaat	gggactgga	gctggagagg	540
aacgggcatg	ctctcgagg	gatgaccagg	cctagagatg	cctcggggc	agaggagaa	600
gggaacagcc	tgggcccaga	gttgcaaca	atcaacctgg	tgggtgccaa	ggggatgatg	660
ttaggggtct	cgggcaacac	ggggagtgg	aagagcagcc	tgttgtagc	catcctggag	720
gagatgcact	tgtctgaggg	ctcgggtggg	gtgcaggaaa	gcttggccta	tgccccccag	780
caggcctgga	tgttcagcgg	gaacatcagg	gagaacatcc	tcattggagg	cgcatatgac	840
aaggcccgat	acctccaggt	gctccactgc	tgtccctcga	atcgggacct	ggaaactctg	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctctgt	ggggcagaaa	960
cagaggatca	gcctggcccg	cgccgtctat	tccgaccgtc	agatctacct	gctccagcac	1020
ccctgtgtct	ctgtggagcg	ccacgtgggg	aagcacattt	ttgaggagtg	cattaagaag	1080
acactcaggg	ggaagcaggg	gctcctgggt	accaccagc	tcagctactt	gcaattttgt	1140
ggccagatca	ttttgttgg	aaatgggaaa	atctgtgaaa	atggaactca	cagtgtagtt	1200
atgcagaaaa	aggggaaaa	tgccccactt	atccagaaga	tgcaacaagg	agccactctg	1260
gacatgttgc	aggacacagc	aaagatagca	gagaagccaa	aggtagaaa	tcaggctctg	1320
gcacctccc	tggaaagatc	tctcaacgga	aatgctgtgc	cggagcatca	gctcacacag	1380
gaggagagga	tggaaagaag	ctccttgagt	tggagggtct	accaccacta	catccaggca	1440
gctggagggt	acatggtctc	ttgcataatt	ttcttctctg	tgggtgctgat	cgtctctotta	1500
acgatctcca	gcttctgggt	gctgagctac	tggttggagc	agggctcggg	gaccaatagc	1560
agccgagaga	gcaatgggaa	catggcagac	ctgggccaaca	ctgcagacaa	tcctcaactg	1620
tccttctacc	agctggtgta	cgggctcaac	gcctgtcttc	tcattctgtg	gggggtctgc	1680
tcctcaggga	ttttcaccaa	ggtcacgagg	aaggcatcca	cggccctgca	caacagctc	1740
ttcaacaagg	ttttccgtct	ccccatgagt	ttctttgaca	ccatcccaat	agggcggtct	1800
ttgaactgct	tcgcaggagg	cttggaacag	ctggaccagg	ctttgcccct	cttttcagag	1860
cagtctctgt	tcctgtcctt	aatgggtgatc	gccgtctctg	tgattgtcag	tgtgtcgtct	1920
ccatatatcc	tgtaaatggg	agccataatc	atggttatct	gcttcattta	ttatatgatg	1980
ttcaagaagg	ccatcggtgt	gttcaagaga	ctggagaact	atagccgggtc	tcctttatct	2040
tcaccatcca	tcaattctct	gcaaggcctg	agctccatcc	atgtctatgg	aaaaactgaa	2100
gacttcatca	gocag					2115

<210> 4

<211> 705

<212> PRT

<213> homo sapiens

<400> 4

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1			5					10					15		
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25				30			
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35					40				45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
			50				55				60				
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
			65			70			75					80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
				85					90					95	
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100				105					110			
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
			115				120					125			
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
			130			135					140				
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
			145			150				155				160	

Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu	165	170	175
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg	180	185	190
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu	195	200	205
His	Lys	Ile	Asn	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys	210	215	220
Gly	Asn	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu	225	230	235
Glu	Met	His	Leu	Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala	245	250	255
Tyr	Val	Pro	Gln	Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn	260	265	270
Ile	Leu	Met	Gly	Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu	275	280	285
His	Cys	Cys	Ser	Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp	290	295	300
Met	Thr	Glu	Ile	Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys	305	310	315
Gln	Arg	Ile	Ser	Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr	325	330	335
Leu	Leu	Asp	Asp	Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His	340	345	350
Ile	Phe	Glu	Glu	Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val	355	360	365
Leu	Val	Thr	His	Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile	370	375	380
Leu	Leu	Glu	Asn	Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu	385	390	395
Met	Gln	Lys	Lys	Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys	405	410	415
Glu	Ala	Thr	Ser	Asp	Met	Leu	Gln	Asp	Thr	Ala	Lys	Ile	Ala	Glu	Lys	420	425	430
Pro	Lys	Val	Glu	Ser	Gln	Ala	Leu	Ala	Thr	Ser	Leu	Glu	Glu	Ser	Leu	435	440	445
Asn	Gly	Asn	Ala	Val	Pro	Glu	His	Gln	Leu	Thr	Gln	Glu	Glu	Glu	Met	450	455	460
Glu	Glu	Gly	Ser	Leu	Ser	Trp	Arg	Val	Tyr	His	His	Tyr	Ile	Gln	Ala	465	470	475
Ala	Gly	Gly	Tyr	Met	Val	Ser	Cys	Ile	Ile	Phe	Phe	Phe	Val	Val	Leu	485	490	495
Ile	Val	Phe	Leu	Thr	Ile	Phe	Ser	Phe	Trp	Trp	Leu	Ser	Tyr	Trp	Leu	500	505	510
Glu	Gln	Gly	Ser	Gly	Thr	Asn	Ser	Ser	Arg	Glu	Ser	Asn	Gly	Thr	Met	515	520	525
Ala	Asp	Leu	Gly	Asn	Ile	Ala	Asp	Asn	Pro	Gln	Leu	Ser	Phe	Tyr	Gln	530	535	540
Leu	Val	Tyr	Gly	Leu	Asn	Ala	Leu	Leu	Leu	Ile	Cys	Val	Gly	Val	Cys	545	550	555
Ser	Ser	Gly	Ile	Phe	Thr	Lys	Val	Thr	Arg	Lys	Ala	Ser	Thr	Ala	Leu	565	570	575
His	Asn	Lys	Leu	Phe	Asn	Lys	Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	580	585	590
Asp	Thr	Ile	Pro	Ile	Gly	Arg	Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	595	600	605

Glu Gln Leu Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val
 610 615 620
 Leu Ser Leu Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser
 625 630 635 640
 Pro Tyr Ile Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile
 645 650 655
 Tyr Tyr Met Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu
 660 665 670
 Asn Tyr Ser Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln
 675 680 685
 Gly Leu Ser Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser
 690 695 700
 Gln
 705

<210> 5
 <211> 3189
 <212> DNA
 <213> homo sapiens

<400> 5
 atgacaagaa tggctgtgaa ggctcagcat cacacatctg aggtcagcga ccagcgcctc 60
 cgtgtgacca gtgaagtctt cacttgcatt aagctgatta aaatgtacac atgggagaaa 120
 ccatttgcaa aaatcattga agacattaaga aggaagggaaa ggaagctatt ggagaagtgc 180
 gggccttgctc agagcctgac aagtataacc ttgttcacac tcccacacagt ggccacagcg 240
 gtctgggttc tcattccacac atccttaaaag ctgaaactca cagcgccaat ggccctcagc 300
 atgctgggctt ccttgaatct ccttcggctg tcagctgtct tcagctcaat tgcagctaaa 360
 ggcttcacga attccaagtc tgcagtgatg aggttcaaga agtttttctt ccagggagagc 420
 cctgtttctt atgtccagac attacaagac ccacgcaaaag ccttggtctt tgaggaggcc 480
 accttgatcat ggcaacagac ctgtcccggg atcgtcaatg gggcacttga gctggagagg 540
 aacgggcatg cttctgaggg gatgaccagg cctagagatg cctcggggcc agagaaagaa 600
 gggaacagcc tgggcccaga gttgcacaag atcaacctgg tgggtgtccaa ggggatgatg 660
 ttagggtctt ggggcaacac ggggagtgtt aagagcagcc tgttgtcagc catcctggag 720
 gagatgcact tgcctcagag ctcggtgggg gtgcagggaa gcttgcccta tgtcccccag 780
 caggccttga tgcctcagcg gaacatcagg gagaacatcc tcatggggagg cgcataatgac 840
 aaggcccgat acctccaggt gctccactgc tgctccctga atcgggacct ggaacttctg 900
 ccttttggag acatgacaga gattggagag cggggcctca acctctctgg ggggcagaaa 960
 cagaggaatca gcttggcccg cgccgtctat tccgaccgtc agatctacct gctggacgac 1020
 cccctgtctt ctgttgagcc ccacgtgggg aagcacattt ttgaggagtg cattaagaag 1080
 acactcaggg ggaagacggt cgtcctgttg acccaccagc tgcagtactt agaattttgt 1140
 ggccagatca ttttgttggg aaatgggaaa atctgtgaaa atggaactca cagttagtta 1200
 atgcagaaaa aggggaaata tgcccgaact atccagaaga tgcacaagga agccactctg 1260
 gacatgttgc aggcacagcg aaagatagca gagaagccaa aggtagaaga tcaggctctg 1320
 gccactccc tggaaagatc tctcaacgga aatgctgtgc cggagcatca gctcaacagc 1380
 gaggaggaga tggaaagagg ctcttgagt tggagggtct accaccacta catccagcca 1440
 gctggaggtt acatggtctc ttgcataatt ttcttcttcg tgggtctgat cgtcttctta 1500
 acgatcttca gcttctgggt gctgagctac tgggttgagc agggctcggg gaccaatagc 1560
 agccgagaga gcaatggaac catggcagac ctgggcaaca tctgacacaa tgcctcaactg 1620
 tccctctacc agcttggtgt agcgttctcc gccctgtctc tcactgtgtg tgggtgtctgc 1680
 tccctcagga ttttcaccaa ggtcacaggg aaggcatcca cgcccttga caacaagctc 1740
 ttcaacagga ttttcgcgtc ccccatgagt ttctttgaca ccatcccaat aggcctcgtt 1800
 tgaactgtt tgcaggggga ctgggaaacag ctggaccagc tcttgcccat cttttcagag 1860
 cagttctctg tctctgtcct aatggtgac gcgcctctgt tgattgtcag ttgtctgtct 1920
 ccatatattc tgtaaatggg agccataatc atggttattt gcttcattta ttaatatgat 1980
 ttcaagaagg ccattcgggt gttcaagaga ctggagaact atagccggtc tcccttatct 2040
 tcccacatcc tcaattctct gcaaggcctg agctccatcc atgtctatgg aaaaactgaa 2100

gacttcatca	gccagtttaa	gaggctgact	gatgcgcaga	ataactacct	gctgttggtt	2160
ctatcttcca	cacgattgat	ggcattgagg	ctggagatca	tgaccaacct	tgtgacctgt	2220
gctgttgccc	tgttcgtggc	ttttggcatt	tcctccaccc	cctactcctt	taaagtcatg	2280
gctgtcaaca	tcgtgctgca	gctggcgctc	agcttccagg	ccactgcccg	gattggcgtg	2340
gagacagag	cacagttcac	ggctgtagag	aggatactgc	agtacatgaa	gatgtgtgtc	2400
tcggaagctc	ctttacacat	ggaaggcaca	agttgtcccc	aggggtggcc	acacgcatgg	2460
gaaatcatat	ttcaggatta	tcacatgaaa	tacagagaca	acacaccacc	cgtgcttccac	2520
ggcatcaacc	tgaccatccg	cggccacgaa	gtggtggcca	tcgtgggaag	gaacggctct	2580
gggaagtcc	ccttgggcat	ggctctcttc	cgctgtgtgg	agcccatggc	agggcggatt	2640
ctcattgacg	gcgtggacat	ttgcagcatc	ggcctggagg	acttgcggtc	caagctctca	2700
gtgatccctc	aagattccagt	gctgctctca	ggaaccatca	gattcaacct	agatcccttt	2760
gaccgtcaca	ctgaccagca	gatctgggat	gccttggaga	ggacattcct	gaccaaggcc	2820
atctcaaaat	tcctcaaaaa	cctgcataca	gatgtgtgtg	aaaacggtgg	aaacttctct	2880
gtgggggaga	ggcagctgct	ctgcattgcc	aggcgtgtgc	ttcgcaactc	caagatcatc	2940
cttatcgatg	aagccacagc	ctccattgac	atggagacag	acacccatgat	cacgcgcaca	3000
atccgtgaag	ccttccaggg	ctgcaccgtg	ctcgtcattg	cccaccgtgt	caccactgtg	3060
ctgaactgtg	accacatcct	ggttatgggc	aatgggaagg	tggtagaatt	tgatcggccg	3120
gaggtactgc	ggaagaagcc	tggtgtcattg	ttgcagcccc	tcattggccac	agccacttct	3180
tcactgaga						3189

<210> 6

<211> 1063

<212> PRT

<213> homo sapiens

<400> 6

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10						15	
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
	50					55					60				
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65					70					75				80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
			85						90					95	
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100					105					110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
115							120					125			
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
130						135					140				
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
145					150					155					160
Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu
			165						170					175	
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg
			180					185					190		
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu
			195				200					205			
His	Lys	Ile	Asn	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys
210						215					220				
Gly	Asn	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu
225					230					235					

Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala
 245 250 255
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn
 260 265 270
 Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu
 275 280 285
 His Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp
 290 295 300
 Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys
 305 310 315 320
 Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr
 325 330 335
 Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His
 340 345 350
 Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val
 355 360 365
 Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile
 370 375 380
 Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu
 385 390 395 400
 Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys
 405 410 415
 Glu Ala Thr Ser Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys
 420 425 430
 Pro Lys Val Glu Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu
 435 440 445
 Asn Gly Asn Ala Val Pro Glu His Gln Leu Thr Gln Glu Glu Met
 450 455 460
 Glu Glu Gly Ser Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala
 465 470 475 480
 Ala Gly Gly Tyr Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu
 485 490 495
 Ile Val Phe Leu Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu
 500 505 510
 Glu Gln Gly Ser Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met
 515 520 525
 Ala Asp Leu Gly Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln
 530 535 540
 Leu Val Tyr Gly Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys
 545 550 555 560
 Ser Ser Gly Ile Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu
 565 570 575
 His Asn Lys Leu Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe
 580 585 590
 Asp Thr Ile Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu
 595 600 605
 Glu Gln Leu Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val
 610 615 620
 Leu Ser Leu Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser
 625 630 635 640
 Pro Tyr Ile Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile
 645 650 655
 Tyr Tyr Met Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu
 660 665 670
 Asn Tyr Ser Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln
 675 680 685

Gly Leu Ser Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser
 690 695 700
 Gln Phe Lys Arg Leu Thr Asp Ala Gln Asn Asn Tyr Leu Leu Leu Phe
 705 710 715 720
 Leu Ser Ser Thr Arg Trp Met Ala Leu Arg Leu Glu Ile Met Thr Asn
 725 730 735
 Leu Val Thr Leu Ala Val Ala Leu Phe Val Ala Phe Gly Ile Ser Ser
 740 745 750
 Thr Pro Tyr Ser Phe Lys Val Met Ala Val Asn Ile Val Leu Gln Leu
 755 760 765
 Ala Ser Ser Phe Gln Ala Thr Ala Arg Ile Gly Leu Glu Thr Glu Ala
 770 775 780
 Gln Phe Thr Ala Val Glu Arg Ile Leu Gln Tyr Met Lys Met Cys Val
 785 790 795 800
 Ser Glu Ala Pro Leu His Met Glu Gly Thr Ser Cys Pro Gln Gly Trp
 805 810 815
 Pro Gln His Gly Glu Ile Ile Phe Gln Asp Tyr His Met Lys Tyr Arg
 820 825 830
 Asp Asn Thr Pro Thr Val Leu His Gly Ile Asn Leu Thr Ile Arg Gly
 835 840 845
 His Glu Val Val Gly Ile Val Gly Arg Thr Gly Ser Gly Lys Ser Ser
 850 855 860
 Leu Gly Met Ala Leu Phe Arg Leu Val Glu Pro Met Ala Gly Arg Ile
 865 870 875 880
 Leu Ile Asp Gly Val Asp Ile Cys Ser Ile Gly Leu Glu Asp Leu Arg
 885 890 895
 Ser Lys Leu Ser Val Ile Pro Gln Asp Pro Val Leu Leu Ser Gly Thr
 900 905 910
 Ile Arg Phe Asn Leu Asp Pro Phe Asp Arg His Thr Asp Gln Gln Ile
 915 920 925
 Trp Asp Ala Leu Glu Arg Thr Phe Leu Thr Lys Ala Ile Ser Lys Phe
 930 935 940
 Pro Lys Lys Leu His Thr Asp Val Val Glu Asn Gly Gly Asn Phe Ser
 945 950 955 960
 Val Gly Glu Arg Gln Leu Leu Cys Ile Ala Arg Ala Val Leu Arg Asn
 965 970 975
 Ser Lys Ile Ile Leu Ile Asp Glu Ala Thr Ala Ser Ile Asp Met Glu
 980 985 990
 Thr Asp Thr Leu Ile Gln Arg Thr Ile Arg Glu Ala Phe Gln Gly Cys
 995 1000 1005
 Thr Val Leu Val Ile Ala His Arg Val Thr Thr Val Leu Asn Cys Asp
 1010 1015 1020
 His Ile Leu Val Met Gly Asn Gly Lys Val Val Glu Phe Asp Arg Pro
 1025 1030 1035 1040
 Glu Val Leu Arg Lys Lys Pro Gly Ser Leu Phe Ala Ala Leu Met Ala
 1045 1050 1055
 Thr Ala Thr Ser Ser Leu Arg
 1060

<210> 7

<211> 1488

<212> DNA

<213> homo sapiens

<400> 7

atgacaagaa tggctgtgaa ggctcagcat cacacatctg aggtcagcga ccagcgcac

60

cggtgtgacca	gtgaagtctt	cacttgcatt	aagctgatta	aaatgtacac	atggggagaaa	120
ccatttgcac	aaatcattga	agacctaaga	aggaaggaaa	ggaagctatt	ggagaagtgc	180
gggttgttgc	agagcctgac	aagtataacc	ttgttcacac	tccccacagt	ggccacagcg	240
gtctgggttc	tcatccacac	atccttaaa	ctgaaactca	cagcgtcaat	ggccttcagc	300
atgctggcct	ccttgaatct	ccttcggctg	tcagttgtct	ttgtgcctat	tgacgtcaaa	360
ggctctacga	attccaaagt	tcagctgatg	aggttcaaga	agtttttctt	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaa	ctctgggtct	tgaggaggcc	480
accttgtcat	ggcaacagac	ctgtcccggg	atcgtcaatg	gggcactgga	gctggagagg	540
aacgggcatg	cttctgaggg	gatgaccagg	cctagagatg	ccctcgggcc	agaggaagaa	600
gggaacagcc	tggggccaga	gttgcaaca	atcaacctgg	tgtgttccaa	ggggatgatg	660
ttaggggtct	ggggcaacac	ggggagtgg	aagagcagcc	tggtgtcagc	catcctggag	720
gagatgcact	tgctcagggg	ctcgtggggg	gtgcaggaaa	gcctggccta	tgccccccag	780
caggcctgga	tcgtcagcgg	gaacatcagg	gagaaacatc	tcattgggag	gcgcatatgac	840
aaggcccgat	acctccaggt	gctccactgc	tgctccctga	atcgggacct	ggaactctct	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctctgg	ggggcagaaa	960
cagaggatca	gctcggcccg	cgccgtctat	tcgcagcctg	agatctacct	gctggcagcg	1020
ccctgtctct	ctgtggacgc	ccacgtgggg	aagcacattt	ttgaggagtg	cattaagaag	1080
acactcaggg	ggaagacggt	cgctctgggt	accaccagcg	tgcatctact	agaattttgt	1140
ggccagatca	ttttgttgga	aaatgggaaa	atctgtgaaa	atggaactca	cagtgaagta	1200
atgcagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgccacaagg	agccactctg	1260
gttttccgct	gcgccatgag	tttctttgac	accatcccaa	taggcccggct	tttgaactcg	1320
ttcgcagggg	acttgggaaca	ctctggaccag	ctctttgccc	tccttttcaga	gcagtttctg	1380
gtcctgtctc	taatgggtgat	cgccgtcctg	ttgattgtca	gtgtgctgtc	tccatatatc	1440
ctgttaatgg	gagccataat	catgggttatt	tgcttcattt	attatatg		1488

<210> 8

<211> 496

<212> PRT

<213> homo sapiens

<400> 8

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10						15	
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
	50				55					60					
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65				70					75					80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
			85					90					95		
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
	100					105						110			
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
	115					120						125			
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
	130				135					140					
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
145				150					155					160	
Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu
			165					170					175		
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg
	180					185						190			
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu

195	200	205
His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys		
210	215	220
Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu		
225	230	235
Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala		
245	250	255
Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn		
260	265	270
Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu		
275	280	285
His Cys Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp		
290	295	300
Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys		
305	310	315
Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr		
325	330	335
Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His		
340	345	350
Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val		
355	360	365
Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile		
370	375	380
Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu		
385	390	395
Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys		
405	410	415
Glu Ala Thr Ser Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile		
420	425	430
Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu		
435	440	445
Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu		
450	455	460
Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile		
465	470	475
Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met		
485	490	495

<210> 9

<211> 1626

<212> DNA

<213> homo sapiens

<400> 9

atgacaagaa	tggctgtgaa	ggctcagcat	cacacatctg	aggctcagcga	ccagcgcctc	60
cgtgtgacca	gtgaagtctc	cactttgcat	aagctgatta	aaatgtacac	atgggagaaa	120
ccatttgcga	aaatcattga	agacctaaga	aggaaggaaa	ggaagctatt	ggagaagtgc	180
gggtgtgttc	agagcctgac	aagtataacc	tgttccatca	tccccacagt	ggccacagcg	240
gtctgggttc	tcattccacac	atccttaaaag	ctgaaactca	cagcgtcaat	ggccttcagc	300
atgtcggcct	ccttgaatct	ccttcggctg	tcagtggtct	ttgtgcctat	tcagtcctaaa	360
gggtccacga	attccaagtc	tgcatgtgat	aggttcaaga	agtttttcc	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaa	ctctgttctt	tgaggaggcc	480
accttgtcat	ggcaacagac	ctgtcccggg	atcgtcaatg	gggcactgga	gctggagagg	540
aacgggcatg	cttctgaggg	gatgaccagg	cctagagatg	cctcggggcc	agaggaagaa	600
gggaacagcc	tgggcccaga	gtgcacaag	atcaacctgg	tggtgtccaa	ggggatgatg	660
ttaggggctc	gcggcaacac	ggggagtggg	aagagcagcc	tggtgtcagc	catcctggag	720

gagatgcact	tgctcgagg	ctcggtggg	gtgcaggaa	gcctggccta	tgccccag	780
caggccctga	tcgtcagcg	gaacatcag	gagaacatcc	tcattgggagg	cgcatatgac	840
aaggcccgat	acctccagg	gctccactgc	tgctccctga	atcgggacct	ggaactctcg	900
ccctttggag	acatgacaga	gattggagag	cggggacctca	acctctctgg	ggggcagaaa	960
cagaggatca	gcctggcccg	cgccgtctat	tcggaccgtc	agatctacct	gctggacgac	1020
ccctgtgtcg	ctgtggacgc	ccacgtgggg	aagcacattt	ttgaggagtg	cattaagaag	1080
acactcagg	ggaagacggt	cgctctggg	accaccacgc	tcgagtactt	agaattttgt	1140
ggccagatca	ttttgttgg	aaatgggaaa	atctgtgaaa	atggaaactca	cagtgaagta	1200
atgcagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgacaaagga	agccacttgc	1260
gttttccgct	gcccctgag	tttctttgac	accatcccaa	tagggccgct	tttgaaactgc	1320
ttcgcagggg	acttggaaaca	gctggaccag	ctcttgccca	ttttttcaga	gcagttcctg	1380
gtcctgtcct	taatgggtgat	cgccgtcctg	ttgattgtca	gtgtgctgtc	tcctatatc	1440
ctgttaatgg	gagccataat	catgggtatt	tgcttcattt	attatatgat	gttcaagaag	1500
gccatcggtg	tgttcaagag	actggagaac	tatagccggt	ctcctttatt	ctccaccatc	1560
ctcaattctc	tgcaaggcct	gagctccatc	catgtctatg	gaaaaactga	agacttcatc	1620
agccag						1626

<210> 10
 <211> 542
 <212> PRT
 <213> homo sapiens

<400> 10
 Met Thr Arg Met Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser
 1 5 10 15
 Asp Gln Arg Ile Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu
 20 25 30
 Ile Lys Met Tyr Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp
 35 40 45
 Leu Arg Arg Lys Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln
 50 55 60
 Ser Leu Thr Ser Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala
 65 70 75 80
 Val Trp Val Leu Ile His Thr Ser Leu Lys Leu Thr Ala Ser
 85 90 95
 Met Ala Phe Ser Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val
 100 105 110
 Phe Phe Val Pro Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala
 115 120 125
 Val Met Arg Phe Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr
 130 135 140
 Val Gln Thr Leu Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala
 145 150 155 160
 Thr Leu Ser Trp Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu
 165 170 175
 Glu Leu Glu Arg Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg
 180 185 190
 Asp Ala Leu Gly Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu
 195 200 205
 His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys
 210 215 220
 Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu
 225 230 235 240
 Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala
 245 250 255
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn

	260		265		270
Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu					
	275		280		285
His Cys Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp					
	290		295		300
Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys					
305		310		315	320
Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr					
	325		330		335
Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His					
	340		345		350
Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val					
	355		360		365
Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile					
	370		375		380
Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu					
385		390		395	400
Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys					
	405		410		415
Glu Ala Thr Ser Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile					
	420		425		430
Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu					
	435		440		445
Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu					
	450		455		460
Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile					
465		470		475	480
Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met					
	485		490		495
Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser					
	500		505		510
Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser					
	515		520		525
Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln					
	530		535		540

<210> 11

<211> 2700

<212> DNA

<213> homo sapiens

<400> 11

atgacaagaa	tggtgtgtgaa	ggctcagcat	cacacatctg	aggtcagcga	ccagcgcatc	60
cgtgtgacca	gtgaagtctt	cacttgcatt	aagctgatta	aaatgtacac	atgggagaaa	120
ccatttgcac	aaatcattga	agacctaaga	aggaagggaa	ggaagctatt	ggagaagtgc	180
gggcttgctc	agagcctgac	aagtataacc	ttgttcatca	tccccacagt	ggccacagcg	240
gtctgggttc	tcctccacac	atccttaaag	ctgaaactca	cagcgtcaat	ggccttcagc	300
atgtgggcct	ccttgaatct	ccttcggctg	tcagtggtct	ttgtgcctat	tcagctcaaa	360
ggtctccaga	attccaagtc	tgccagtgat	aggctcaaga	agtttttcc	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaa	ctctggtctt	tgaggaggcc	480
acctgtctct	ggcaacagac	ctgtcccggt	atcgtcaatg	gggcactgga	gctggagagg	540
aacgggcatc	cttctgagg	gatgaccagg	cctagagatg	ccctcggggc	agaggaagaa	600
gggaacagcc	tgggcccaga	gttgacaca	atcaacctgg	tggtgtccaa	ggggatgatg	660
ttaggggtct	gcggcaacac	ggggagtggt	aagagcagcc	tggtgtcagc	catcctggag	720
gagatgcact	tgctcagggt	ctcgggtggg	gtgcagggaa	ccctcgcccta	tgctccccag	780
caggcctgga	tcgtcagcgg	gaacatcagg	gagaacatcc	tcattggagg	cgcatatgat	840

aagggccgat	acctccaggt	gctccactgc	tgtccctgta	atcgggagct	ggaactctgt	900
ccctttggag	acatgacaga	gattggagag	cggggacctca	acctctcttg	ggggcagaaa	960
cagaggatca	gcttggcccg	cgccgtctat	tcgagaccgt	agatctacct	gctggacgac	1020
ccctgtctgc	ctgtggagcg	ccacgtgggg	aagcacattt	ttgaggagtg	cattaagaag	1080
acctcaggg	ggaagacggt	cgctctgggt	acccaccagc	tgcagtaact	agaattttgt	1140
ggccagatca	ttttgttgga	aaatgggaaa	atctgtgaaa	atggaactca	cagtgtggtta	1200
atcgagaaaa	aggggaaaaa	tgcccaactt	atccagaaga	tgcacaagga	agccactctg	1260
gttttccgt	gccccatgag	tttttttgac	accatcccaa	tagggccggt	tttgaactgc	1320
ttcgacggg	acttgggaaca	gctggaccag	ctcttgccea	tcttttcaga	gcagttctctg	1380
gtcctgtcct	taattggtgat	cgccgtctct	ttgattgtca	gtgtgctgtc	tccatatatc	1440
ctgttaattg	gagccataat	catggttatt	tgcttctatt	attatatgat	gttcaagaag	1500
gccatcggtg	gtttcaagag	actggagaac	tatagccggt	ctcctttatt	ctccaccatc	1560
ctcaattctc	tgcaaggcct	gagctccatc	catgtctatg	gaaaaactga	agacttcatc	1620
agccagttta	agaggctgac	tgatgcgcag	aataactacc	tgctgttggt	tctatcttcc	1680
acacgatgga	tggcattgag	gctggagatc	atgaccaacc	ttgtgacctt	ggctgttgcc	1740
ctgttcctgg	cttttggcat	ttctccacc	ccctactcct	ttaaagtcat	ggctgtcaac	1800
atcgtgtgc	agctggcgct	cagcttccag	gccactgcc	ggattgtgct	ggagacagag	1860
gcacagttca	cggtgttaga	gaggatactg	cagtacatga	agatgtgtgt	ctcggaagct	1920
ctttatcaca	tggaaaggcac	aagtgttccc	caggggtggc	cacagcatgg	ggaaatcata	1980
tttcagagatt	atcacatgaa	atacagagac	aacacaccca	ccgtgcttca	cggcatcaac	2040
ctgaccatcc	cgggccacga	agtggtgggc	atcgtgggaa	ggacgggctc	tgggaagtec	2100
tccttgggca	tggctctctt	ccgcttggtg	gagcccatgg	caggccggat	tctcattgac	2160
ggcgtggaca	tttgcagcat	cggcctggag	gacttgcggt	ccaagctctc	agtgatccct	2220
caagatccag	tgtgtctctc	aggaaccatc	agattcaacc	tagatccctt	tgaccgtcac	2280
actgaccagc	agatctggga	tgccctggag	aggacattcc	tgaccaaggc	catctcaaac	2340
ttccccaaaa	agctgcatac	agatgtgggt	gaaaacgggt	gaaactcttc	tgtgggggag	2400
aggcagctgc	tctgcatttc	cagggctgtg	cttcgcaact	ccaagatcat	ccttatcgat	2460
gaagccacag	ctccatttga	catgagagac	gacacccctg	tcacgcgcac	aatccgtgaa	2520
gcccttcagg	cgctgcacgt	gctgtcatt	gccaccggt	tcaccactgt	gctgaactgt	2580
gaccacatcc	tgggttatgg	caatgggaag	gtggtagaat	ttgatcgccc	ggaggtactg	2640
cggaagaagc	ctgggtcatt	gttcgcagcc	ctcatggcca	cagccacttc	ttcactgaga	2700

<210> 12

<211> 900

<212> PRT

<213> homo sapiens

<400> 12

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10					15		
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
	50				55					60					
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65				70						75				80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
			85					90					95		
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100				105						110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
			115				120						125		
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
	130					135					140				

Val Gln Thr Leu Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala
 145 150 155 160
 Thr Leu Ser Trp Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu
 165 170 175
 Glu Leu Glu Arg Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg
 180 185 190
 Asp Ala Leu Gly Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu
 195 200 205
 His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys
 210 215 220
 Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu
 225 230 235 240
 Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala
 245 250 255
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn
 260 265 270
 Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu
 275 280 285
 His Cys Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp
 290 295 300
 Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys
 305 310 315 320
 Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr
 325 330 335
 Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His
 340 345 350
 Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val
 355 360 365
 Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile
 370 375 380
 Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu
 385 390 395 400
 Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys
 405 410 415
 Glu Ala Thr Ser Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile
 420 425 430
 Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu
 435 440 445
 Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu
 450 455 460
 Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile
 465 470 475 480
 Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met
 485 490 495
 Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser
 500 505 510
 Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser
 515 520 525
 Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln Phe Lys
 530 535 540
 Arg Leu Thr Asp Ala Gln Asn Asn Tyr Leu Leu Leu Phe Leu Ser Ser
 545 550 555 560
 Thr Arg Trp Met Ala Leu Arg Leu Glu Ile Met Thr Asn Leu Val Thr
 565 570 575
 Leu Ala Val Ala Leu Phe Val Ala Phe Gly Ile Ser Ser Thr Pro Tyr
 580 585 590

Ser Phe Lys Val Met Ala Val Asn Ile Val Leu Gln Leu Ala Ser Ser
 595 600 605
 Phe Gln Ala Thr Ala Arg Ile Gly Leu Glu Thr Glu Ala Gln Phe Thr
 610 615 620
 Ala Val Glu Arg Ile Leu Gln Tyr Met Lys Met Cys Val Ser Glu Ala
 625 630 635 640
 Pro Leu His Met Glu Gly Thr Ser Cys Pro Gln Gly Trp Pro Gln His
 645 650 655
 Gly Glu Ile Ile Phe Gln Asp Tyr His Met Lys Tyr Arg Asp Asn Thr
 660 665 670
 Pro Thr Val Leu His Gly Ile Asn Leu Thr Ile Arg Gly His Glu Val
 675 680 685
 Val Gly Ile Val Gly Arg Thr Gly Ser Gly Lys Ser Ser Leu Gly Met
 690 695 700
 Ala Leu Phe Arg Leu Val Glu Pro Met Ala Gly Arg Ile Leu Ile Asp
 705 710 715 720
 Gly Val Asp Ile Cys Ser Ile Gly Leu Glu Asp Leu Arg Ser Lys Leu
 725 730 735
 Ser Val Ile Pro Gln Asp Pro Val Leu Leu Ser Gly Thr Ile Arg Phe
 740 745 750
 Asn Leu Asp Pro Phe Asp Arg His Thr Asp Gln Gln Ile Trp Asp Ala
 755 760 765
 Leu Glu Arg Thr Phe Leu Thr Lys Ala Ile Ser Lys Phe Pro Lys Lys
 770 775 780
 Leu His Thr Asp Val Val Glu Asn Gly Gly Asn Phe Ser Val Gly Glu
 785 790 795 800
 Arg Gln Leu Leu Cys Ile Ala Arg Ala Val Leu Arg Asn Ser Lys Ile
 805 810 815
 Ile Leu Ile Asp Glu Ala Thr Ala Ser Ile Asp Met Glu Thr Asp Thr
 820 825 830
 Leu Ile Gln Arg Thr Ile Arg Glu Ala Phe Gln Gly Cys Thr Val Leu
 835 840 845
 Val Ile Ala His Arg Val Thr Thr Val Leu Asn Cys Asp His Ile Leu
 850 855 860
 Val Met Gly Asn Gly Lys Val Val Glu Phe Asp Arg Pro Glu Val Leu
 865 870 875 880
 Arg Lys Lys Pro Gly Ser Leu Phe Ala Ala Leu Met Ala Thr Ala Thr
 885 890 895
 Ser Ser Leu Arg
 900

<210> 13

<211> 2937

<212> DNA

<213> homo sapiens

<400> 13

atgactagga	agaggacata	ctgggtgcc	aactcttctg	gtggcctcgt	gaatcgtggc	60
atcgacatag	gcgatgacat	ggtttcagga	cttattttata	aaacctatac	ttcccaagat	120
ggccctcgga	gtcagcaaga	gagaaatcct	gaggctccag	ggagggcagc	tgccccaccg	180
tgggggaagt	atgatgctgc	cttgagaacc	atgattccct	tcggtcccaa	gcgaggtgtt	240
cctgcccccc	agccccctgga	caatgctggc	ctgtttcctc	acctcaccgt	gcatgggctc	300
accgccctca	tgatccaaag	cttacggagt	cgcttagatg	agaacaccat	ccctccactg	360
tcagtccatg	atgcctcaga	caaaaatgtc	caagggtctc	accgcctttg	ggaagaagaa	420
gtctcaaggc	gagggattga	aaaagcttca	gtgcttctgg	tgatgctgag	gttccagaga	480
acaaggttga	ttttcgatgc	acttctgggc	atctgcttct	gcattgccag	tgtactcggg	540

ccaatatgga ttataccaaa gatcctggaa tattcagaag agcagttggg gaatgtgttc 600
 catggagttg gactctgttt tgcctctttt ctctccgaat gtgtgaagtc tctgagtttc 660
 tctccagatt ggatcatcaa ccaacgcaca gccatcagggt tccaagcaga tgtttcctcc 720
 tttgcctttg agaagctcat ccaatttaag tctgtaatac acatcaccct aggagagggc 780
 atcagctttt tcacgggtga tgtaaactac ctgtttgaag ggggtgtgcta tggaccctta 840
 gtactgatca ctgtgcgcat gctggctatc tgcagcatct ctctctactt catatttgga 900
 tacactgcat ttattgcat ctatgtctat ctctctgttt tccacttgga ggtattcatg 960
 acaagaattg ctgtgaaggc tcagcatcac acatctgagg tcacgacca gccatccgt 1020
 gtgcacaggg aagttctctc ttgcattaa gtgattaaaa tgtacacatg ggagaaacca 1080
 ttcaaaaaa tcattgaaag cctaagaagg aaggaaagga agctatttga gaagtgcagg 1140
 cttgtccaga gcctgacaag tataaccttg ttcacatccc ccacagtgcc cacagcggtc 1200
 tgggtttctc tccacacatc cttaaaagctg aaactcacag cgtcaatggc ctccagcatg 1260
 ctggcctcct tgaattctct tggcgtgtca gtgttctttg tgcctatggc agtcaagggt 1320
 ctacgaattt ccaagtctgc agtgatgagg ttcaagaagt ttttctccca ggagagccct 1380
 gttttctatg tccagacatt acaagacccc agcaaaagctc tggctcttga ggaggccacc 1440
 ttgtcatggc aacagacctg tcccggggtc gtcaatgggg cactggagct ggagaggaaac 1500
 gggcatgctt ctgagggggt gaccaggcct agagatgccc tccggggcaga ggaagaaggg 1560
 aacagcctgt gccacaggtt gcacaagatc aaactggttg tgtccaaagg gatgatgtta 1620
 ggggtctgct gcaacacagg gagtggtaag agcagcctgt tgtcagccat cctggaggag 1680
 atgcacttgc tgcaggggct ggtgggggtg cagggaagcc tggcctatgt cccccagag 1740
 gcttgatgc tcacggggaa catcaggggg aacatcctca tggggaggcg atatgacaag 1800
 gcccgatacc tccaggtgct ccaactgtgc tccctgaatc gggacctgga actctgtccc 1860
 tttggagaca tgacagagat tggagagcgg ggcctcaacc tctctggggg gcagaacacg 1920
 aggatcagcc tggcccgccg cgtctattcc gaccgtcaga tctacctgtc ggacgacccc 1980
 ctgtctcttg tggagcgcca cgtggggaag cacatttttg aggagtgcac taagaagaca 2040
 ctacagggga agacgggtgt cctggtgacc caccagctgc agtacttaga attttgtggc 2100
 cagatcattt tgttggaaaa tgggaaaaatc tgtgaaaaat gaactcacag tgagttaatg 2160
 cagaaaaagg ggaatatatgc ccaacttatc cagaagatgc acaaggaaag cacttcggac 2220
 atgttgcagg acacagcaaa gatagcagag aagccaaagg tagaaagtca ggctctggcc 2280
 acctcccggt aagagtctct caacggaaat gctgtgcggg agcatcagct cacacagagc 2340
 gaggagatgg aagaaggctc cttaggttgg agggcttacc accactacat ccaggcagct 2400
 ggagggttaca tggctctctg cataatttcc ttctctgtgg tctgtatcgt ctcttaaacg 2460
 atcttcagct tctggtggtc gactactagg ttggagcagg gctcggggac caatagcagc 2520
 cgagagagca atggaacatc ggcagacctg ggcaacattg cagacaatcc tcaactgtcc 2580
 ttctaccagg tgggtgacgg gctcaacgcc ctgctctcca tctgtgtggg ggtctgtccc 2640
 tcagggtatt tcaccaaggt caccaggaag gcattccagg ccctgcacaa caagctcttc 2700
 aacaaggttt tccgctgccc catgagtttc ttgacacca tcccaatagg ccggcttttg 2760
 aactgcttcg caggggacct ggaacagctg gaccagctct tgcccatctt ttcagagcag 2820
 ttctgggtcc tgtccttaat ggtgatcgcc gtcctgttga ttgtcagttg gctgtctcca 2880
 tatatcctgt taatgggagc cataatcatg gttatttgc tcatattatta tatgtga 2937

<210> 14
 <211> 975
 <212> PRT
 <213> homo sapiens

<400> 14
 Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu
 1 5 10 15
 Val Asn Arg Gly Ile Asp Ile Gly Asp Asp Met Val Ser Gly Leu Ile
 20 25 30
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg
 35 40 45
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr
 50 55 60
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe

65	70	75	80
Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp			
	85	90	95
Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn			
	100	105	110
Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln			
	115	120	125
Arg Leu His Arg Leu Trp Glu Glu Val Ser Arg Arg Gly Ile Glu			
	130	135	140
Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu			
	145	150	155
Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu			
	165	170	175
Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln			
	180	185	190
Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu			
	195	200	205
Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn			
	210	215	220
Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe			
	225	230	235
Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu			
	245	250	255
Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val			
	260	265	270
Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys			
	275	280	285
Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile			
	290	295	300
Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met			
	305	310	315
Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile			
	325	330	335
Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr			
	340	345	350
Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys			
	355	360	365
Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser			
	370	375	380
Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu			
	385	390	395
Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser			
	405	410	415
Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro			
	420	425	430
Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe			
	435	440	445
Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu			
	450	455	460
Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp			
	465	470	475
Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg			
	485	490	495
Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly			
	500	505	510
Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn			

515	520	525
Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly		
530	535	540
Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu		
545	550	555
Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln		
565	570	575
Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly		
580	585	590
Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser		
595	600	605
Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile		
610	615	620
Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser		
625	630	635
Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp		
645	650	655
Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu		
660	665	670
Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His		
675	680	685
Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn		
690	695	700
Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys		
705	710	715
Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser		
725	730	735
Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys Pro Lys Val Glu		
740	745	750
Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu Asn Gly Asn Ala		
755	760	765
Val Pro Glu His Gln Leu Thr Gln Glu Glu Met Glu Glu Gly Ser		
770	775	780
Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala Ala Gly Gly Tyr		
785	790	795
Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu Ile Val Phe Leu		
805	810	815
Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu Glu Gln Gly Ser		
820	825	830
Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met Ala Asp Leu Gly		
835	840	845
Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln Leu Val Tyr Gly		
850	855	860
Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys Ser Ser Gly Ile		
865	870	875
Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu His Asn Lys Leu		
885	890	895
Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro		
900	905	910
Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp		
915	920	925
Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met		
930	935	940
Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu		
945	950	955
Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met		960

<210> 15
 <211> 3075
 <212> DNA
 <213> homo sapiens

<400> 15

atgactagga	agaggacata	ctgggtgccc	aactctctctg	gtggcctcgt	gaatcgtggc	60
atcgacatag	gcgatgacat	ggtttcagga	cttatttata	aaacctatac	tctccaagat	120
ggccccctgga	gtcagacaaga	gagaaatcct	gaggtctccag	ggaggggcagc	tgtcccaccg	180
tgggggaagt	atgatgtctgc	cttgagaace	atgattccct	tccgtcccaa	gcgcagggttt	240
cctgcccccc	agcccttggga	caatgctggc	ctgtttctct	acctcaccgt	gtcatggctc	300
accocgcctca	tgatccaaag	cttacggagt	cgcttagatg	agaacacccat	ccctccactg	360
tcagtcctatg	atgcctcaga	caaaaatgtc	caaaggcttc	accgcctttg	ggaagaagaa	420
gtctcaaggc	gagggattga	aaaagcttca	gtgctctcgg	tgatgctgag	gttccagaga	480
acaaggttga	ttttcgatgc	acttctgggc	atctgcttct	gcattgccag	tgactctggg	540
ccaatatgga	ttataccaaa	gatcctggaa	tattcagaag	agcagttggg	gaatgtgtgc	600
catggagtgg	gactctgctt	tgcccttttt	ctctccgaat	gtgtgaagtc	tctgagtttc	660
tctctcagtt	ggatcatcaa	ccaacgcaca	gccatcaggt	tccaagcagc	tgtttctccc	720
tttgctcttg	agaagctcat	ccaatttaag	tctgtaatac	acatcacctc	aggagagggc	780
atcagcttct	tcacccgtga	tgtaaaactac	ctgtttgaag	gggtgtgcta	tggaccccta	840
gtactgtaca	cctgcgcatc	gctggctcatc	tgacagcttt	cttctacttt	cattatttga	900
tacactgcat	ttattgcatc	cttatgctat	ctcctgggtt	tcccactgga	ggatattcatg	960
acaagaatgg	ctgtgaaggg	tcagcatcac	acatctgagg	tcagcgacca	gcgcctccgt	1020
gtgacagctg	aagttctcac	ttgcattaag	ctgattaaaa	tgtaacacat	ggagaaacca	1080
tttgcacaaa	tcattgaaga	cctaagaagg	aaggaaagga	agctattgga	gaatgctggg	1140
cttgtccaga	gcctgacaag	tataaccttg	ttcatcatcc	ccacagtggc	cacagcggtc	1200
tgggtttctca	tcacacatca	cttaaaagct	aaactcacag	cgctcaatggc	cttcacagctg	1260
ctggcctcct	tgaattctct	tcggctgtca	gtgttctttg	tgccatttgc	agtcacaagg	1320
ctcacaagatt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctccca	ggagagccct	1380
gttttctatg	tcacagacatt	acaagacccc	agcaagctc	tggtctttga	ggagccaccc	1440
ttgtcatggc	aacagacctg	tcccgggatac	gtcaatgggg	cactggagct	ggagaggaac	1500
gggcatgctt	ctgaggggat	gaccaggcct	agagatgccc	ctgggcccaga	ggaagaaggg	1560
aaacgcctgg	gccacagatt	gcacaagatc	aaactgtgtg	tgtccaaggg	gatgatgtta	1620
gggtctctgc	gcaaacccgg	gagtggttaag	agcagcctgt	tgctcagcat	cctggaggag	1680
atgcacttgc	tcaggggctc	ctgaggggtg	cagggaagcc	tgccctatgt	ccccagcag	1740
gcctggatgc	tcagccggaa	catcaggagg	aaactctcca	tgggagggcg	atatgacaa	1800
gcccgatacc	tccaggtgct	ccactgctgc	tccttgaaic	gggacctcga	acttctgcc	1860
tttgagagaca	tgacagagat	tggagagcgg	ggcctcaacc	tctctggggg	gcagaaacag	1920
aggatcagcc	tggcccgccg	cgctattctc	gacccgtcaga	ttactcgtct	ggacgacccc	1980
ctgtctctgt	tggacgccc	cgctggggaag	cacatttttg	aggagtgcat	taagaagaca	2040
ctcaggggga	agacggtcgt	cctgtgtgacc	caccagctgc	agtacttaga	attttgtggc	2100
cagatcattt	tgttggaata	tgggaaatac	tgtaaaaatg	gaactcacac	tgagtttaag	2160
cagaaaaagg	ggaaaatagc	ccaactatc	cagaagatgc	acaaggaaag	caactcgga	2220
atgttgcagg	acacagcaaa	gatagcagag	aagccaaaag	tagaaagtc	ggctctggcc	2280
acctcctctg	aagagttctc	caacggaaat	gctgtgccgg	agcatcagct	cacacagagc	2340
gaggagatgg	aagaaggctc	cttgagttgg	agggctctacc	accactacat	ccaggcagct	2400
ggagggttaca	tggtctcttg	cataattttc	ttctctgtgg	tgctgatctg	cttctttaag	2460
atcttcagct	tctgtgtgct	gagctactgg	tggagcagg	gctcggggac	caatagcagc	2520
cgagagagca	atggaaccat	ggcagacctg	ggcaaacatc	cagacaactc	tcaactgtcc	2580
tctaccagc	tggtgtacgg	gctcaacgcc	ctgctctcca	tctgtgtggg	ggctctgtcc	2640
tcagggaatt	tcaccaaggt	cacaggaag	gctctccacg	ccctgcacaa	caagctcttc	2700
aaacaaggttt	tccgctgccc	catgagtttc	tttgacacca	tcccataagg	ccggtttttg	2760
aactgcttgc	caggggactt	ggaacagctg	gaccagctct	tgccactctt	ttcagagcag	2820
ttctctgtcc	tgtccttaat	ggtgatcgcc	gtcctgttga	ttgtcagttg	gctgtctcca	2880

tatatcctgt taatgggagc cataatcatg gttatttgct tcatttatta tatgatgttc 2940
 aagaaggcca tcgggtgttt caagagactg gagaactata gccggctccc tttattctcc 3000
 cacatctcta attctctgca aggcctgagc tccatccatg tctatggaaa aactgaagac 3060
 ttcacagcc agtga 3075

<210> 16
 <211> 1021
 <212> PRT
 <213> homo sapiens

<400> 16
 Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu
 1 5 10 15
 Val Asn Arg Gly Ile Asp Ile Gly Asp Met Val Ser Gly Leu Ile
 20 25 30
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg
 35 40 45
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr
 50 55 60
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe
 65 70 75 80
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp
 85 90 95
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn
 100 105 110
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln
 115 120 125
 Arg Leu His Arg Leu Trp Glu Glu Val Ser Arg Arg Gly Ile Glu
 130 135 140
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu
 145 150 155 160
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu
 165 170 175
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln
 180 185 190
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu
 195 200 205
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn
 210 215 220
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe
 225 230 235 240
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu
 245 250 255
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val
 260 265 270
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys
 275 280 285
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile
 290 295 300
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met
 305 310 315 320
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile
 325 330 335
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr
 340 345 350
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys

355	360	365
Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser		
370	375	380
Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu		
385	390	395
Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser		
405	410	415
Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro		
420	425	430
Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe		
435	440	445
Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu		
450	455	460
Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp		
465	470	475
Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg		
485	490	495
Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly		
500	505	510
Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn		
515	520	525
Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly		
530	535	540
Ser Gly Lys Ser Ser Leu Ser Ala Ile Leu Glu Glu Met His Leu		
545	550	555
Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln		
565	570	575
Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly		
580	585	590
Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser		
595	600	605
Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile		
610	615	620
Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser		
625	630	635
Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp		
645	650	655
Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu		
660	665	670
Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His		
675	680	685
Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn		
690	695	700
Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys		
705	710	715
Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser		
725	730	735
Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys Pro Lys Val Glu		
740	745	750
Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu Asn Gly Asn Ala		
755	760	765
Val Pro Glu His Gln Leu Thr Gln Glu Glu Glu Met Glu Glu Gly Ser		
770	775	780
Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala Ala Gly Gly Tyr		
785	790	795
Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu Ile Val Phe Leu		
		800

805 810 815
 Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu Glu Gln Gly Ser
 820 825 830
 Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met Ala Asp Leu Gly
 835 840 845
 Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln Leu Val Tyr Gly
 850 855 860
 Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys Ser Ser Gly Ile
 865 870 875 880
 Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu His Asn Lys Leu
 885 890 895
 Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro
 900 905 910
 Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp
 915 920 925
 Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met
 930 935 940
 Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu
 945 950 955 960
 Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met Met
 965 970 975
 Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser Arg
 980 985 990
 Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser Ser
 995 1000 1005
 Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln
 1010 1015 1020

<210> 17
 <211> 4149
 <212> DNA
 <213> homo sapiens

<400> 17
 atgactagga agaggacata ctgggtgcc aactcttctg gtggcctcgt gaatcgtggc 60
 atcgacatag gcgatgacat ggtttcagga cttatttata aaacctatac tctccaagat 120
 ggccctctgga gtcagcaaga gagaaatcct gaggctccag ggagggcagc tgtcccacgc 180
 tgggggaagt atgatctgctg cttgagaacc atgattccct tccgtcccaa gccgaggttt 240
 cctgcccccc agccctctgga caatgctggc ctgttctcct acctcacgct gtcatcgctc 300
 accccgctca tgatccaaag cttacggagt cgcttagatg agaaccacat cctccactg 360
 tcagtccatg atgcctcaga caaaaatgtc caaaggcttc accgccttg ggaagaagaa 420
 gtctcaaggc gagggattga aaaaacttca gtgcttctgg tgatgctgag gtccagaga 480
 acaaggttga ttttcgatgc acttctgggc atctgtctct gcattgccag tgtactcggg 540
 coaatattga ttataccaaa gatctcgga tattcagaag agcagttggg gaatgttgc 600
 catggagtgg gactctgctt tgcccttttt ctctccgaat gtgtgaagtc tctgactctc 660
 tctctccatg ggatcatcaa ccaacgcaca gccatcaggt tccaagcagc tgtttctctc 720
 tttgcctttg agaagctcat ccaatttaag tctgtaatac acatcacctc aggagagggc 780
 atcagcttct tcaccggtga gttaaactac ctgtttgaag ggggtgtgcta tggaccctga 840
 gtaactgatca cctgcgcac gtggtctcat tgcagcattt ctctctactt cattattgga 900
 tacactgcat ttattgccat cttatgctat ctctcgtttt tcccactgga ggtattcatg 960
 acaagaatgg cttggaaggc tcagcatcac acatctgagg tcagcgacca gcgcatccgt 1020
 gtgaccagtg aagtctcac ttgcattaag ctgattaaaa tgtacacatg ggagaacca 1080
 ttgcaaaaaa tcattgaaga cctaagaagg aaggaaaagg agctattgga gaagtgcggg 1140
 cttgtccaga gcctgacaag tataaccttg ttcacatcc ccacagtggc cacagcggtc 1200
 tgggttctca tccacacct cttaaagctg aaactcacag cgtcaatggc ctccagcatg 1260
 ctggcctcct tgaattctct tcggctgtca gtgttctttg tgctattggc agtcaaaagg 1320

ctcacgaatt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctctca	ggagagccct	1380
gttttctatg	tccagacatt	acaagacccc	agcaaaagctc	tgggtcttga	ggagggcaacc	1440
ttgtcatgvc	aacagacctg	tcccgggagc	gtcaatgggg	cactggagct	ggagaggaaac	1500
gggcatgctt	ctgaggggat	gaccaggcct	agagatgccc	tcggggccaga	ggaagaagggg	1560
aacagagctg	gcccagagtt	gcacaagatc	aacctgggtg	gtccaagggg	gatgatgtta	1620
ggggctctgc	gcaacacggg	gagtggttaa	agcagcctgt	tgtcagccat	cctggaggag	1680
atgcacttgc	tcgaggggctc	ggtgggggtg	cagggaagcc	tggcctatgt	ccccagcag	1740
gcctggatcg	tcagcgggaa	catcaggggag	aacatcctca	tggggaggcg	atatgacaag	1800
gcccagatacc	tccaggtgct	ccactgtctc	tccctgaatc	gggacctgga	actctgcccc	1860
ttttggagaca	tgacagagat	tggagagcgg	ggcctcaacc	tctctggggg	gcagaaacag	1920
aggatcagcc	tggcccgcgc	cgtctattcc	gaccgtcaaga	tctacctgct	ggacgacccc	1980
ctgtctgtcg	tggagcccca	cgtggggaag	cacatttttg	aggagtgcac	taagaagaca	2040
ctcaggggga	agacggtcgt	cctgggtgacc	caccagctgc	agtacttaga	attttgtggc	2100
cgatcatttt	tgttggaaaa	tgggaaaatc	tgtgaaaaat	gaactcagag	tgagtttaatg	2160
cagaaaaagg	ggaaaatagc	ccaacttata	cagaagatgc	acaaggaagc	cactctcgagc	2220
atgttgcagg	acacagacaa	gatagcagag	aagccaaagg	tagaaagtc	ggctctggccc	2280
actcctctgg	aagagtctct	caacggaaat	gctgtgccgg	agcactcagc	ccacagaggag	2340
gaggagatgg	aagaaggctc	ccttgagttgg	agggtctacc	accactacat	ccaggcagct	2400
ggagggtaca	tgttctcttg	cataattttc	ttctctctgg	tgtgatcgt	cttcttaacg	2460
atcttcagct	tctgggtggc	gagctactgg	tgggagcagg	gctcggggag	caatgacagc	2520
cgagagagca	atggaaacct	ggcagacctg	ggcaacattg	cgagacaatc	tcaactgtccc	2580
tcttaccagc	tgggtgacgg	gctcaacgac	ctctctctca	tctgtgtggg	ggctctgctcc	2640
tcagggattt	tcaccaagg	cacgagggaag	gcattccagg	ccctgcacaa	caagctcttc	2700
aacaagggtt	tcgcctgccc	catgagtttc	tttgacacca	tcccaatagg	ccggcttttg	2760
aactgcttcg	cagggggact	ggaaacagctg	gaccagctct	tgccctattt	tccagagcag	2820
tctctgtctc	tgtctctaat	ggtgatgcgc	gtcctgttga	ttgtcagttg	gctgtctcca	2880
tatatcttgt	taattgggag	cataatcatg	gttattttgt	tcatttatta	tatgatgttc	2940
aagaaggcca	tcgggtgtgt	caagagactg	gagaactata	gcgggtctcc	tttattctcc	3000
cacatctcca	attctctgca	aggcctgagc	tccatccatg	tctatggaaa	aactgaagac	3060
ttcatcagcc	agttttaagag	gctgactgat	gcgcagaata	actacctgtc	gttgtttcta	3120
tcttccacac	gatggatggc	attgaggctg	gagatcatga	ccaaccttgt	gaccttggct	3180
gttgccctgt	tctgtgcttt	tggcattttc	tcacccccc	actcctttaa	agtcatggct	3240
gtcaacatct	tgtctcagct	ggcgtccagc	ttccaggcca	ctgcctggat	tggcttggag	3300
acagaggcac	agttccagcc	tgtagagagg	atactgcagt	acatgaagat	gtgtgtctcg	3360
gaagctcctt	tacacatgga	aggcacaagt	tgtccccagg	ggtggccaca	gcattggggaa	3420
atcatatttc	aggattatca	catgaaatc	agagacaaca	cacccaccgt	gcttccagggc	3480
atcaacctga	ccatccggcg	ccacgaagtg	gtgggcatcg	tgggaaggac	gggctctggg	3540
aagtctctct	tgggcatggc	tctctctcgc	ctgggtggagc	ccatggcgagg	ccggattctc	3600
attgacggcg	tggacatttg	cagcatcgcc	ctggaggact	tgcgggtccaa	gctctcagtg	3660
atccctcaag	atccagtgct	gctctcagga	accatcagat	tcaacctaga	tcctcttgac	3720
cgctcacact	accagcagat	ctgggagctc	ttggagagga	catctctgac	caaggccatc	3780
tcaaaagtcc	ccaaaaagct	gcatacagat	gtggtggaaa	acgggtggaaa	cttctctgtg	3840
ggggagagag	agctgctctg	cattgccagg	gctgtgcttc	gcaactccaa	gatcatcctt	3900
atcgatgaag	ccacagcctc	cattgacatg	gagacagaca	ccttgatcca	gcgcacaatc	3960
cgtgaagcct	tccaggggctg	caccgtgctc	gtcaattgcc	accggtgtac	cactgtgtcg	4020
aactgtgacc	acatcctggt	tatgggcaat	gggaagtggt	tagaatttga	tggcccgag	4080
gtactcggga	agaagcctgg	gtcattgttc	gcagccctca	tggccacagc	cacttcttca	4140
ctgagataaa						4149

<210> 18
 <211> 1379
 <212> PRT
 <213> homo sapiens

<400> 18
 Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu

1 5 10 15
 Val Asn Arg Gly Ile Asp Ile Gly Asp Asp Met Val Ser Gly Leu Ile
 20 25 30
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg
 35 40 45
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr
 50 55 60
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe
 65 70 75 80
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp
 85 90 95
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn
 100 105 110
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln
 115 120 125
 Arg Leu His Arg Leu Trp Glu Glu Glu Val Ser Arg Arg Gly Ile Glu
 130 135 140
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu
 145 150 155 160
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu
 165 170 175
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln
 180 185 190
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu
 195 200 205
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn
 210 215 220
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe
 225 230 235 240
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu
 245 250 255
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val
 260 265 270
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys
 275 280 285
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile
 290 295 300
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met
 305 310 315 320
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile
 325 330 335
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr
 340 345 350
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys
 355 360 365
 Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser
 370 375 380
 Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu
 385 390 395 400
 Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser
 405 410 415
 Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro
 420 425 430
 Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe
 435 440 445
 Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu

450	455	460
Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp		
465	470	475
Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg		480
	485	490
Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly		495
	500	505
Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn		510
	515	520
Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly		525
	530	535
Ser Gly Lys Ser Ser Leu Ser Ala Ile Leu Glu Glu Met His Leu		540
	545	550
Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln		555
	560	565
Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly		570
	580	585
Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser		590
	595	600
Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile		605
	610	615
Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser		620
	625	630
Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp		635
	640	645
Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu		650
	655	660
Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His		665
	670	675
Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn		680
	685	690
Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys		695
	700	705
Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser		710
	715	720
Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys Pro Lys Val Glu		725
	730	735
Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu Asn Gly Asn Ala		740
	745	750
Val Pro Glu His Gln Leu Thr Gln Glu Glu Glu Met Glu Glu Gly Ser		755
	760	765
Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala Ala Gly Gly Tyr		770
	775	780
Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu Ile Val Phe Leu		785
	790	795
Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu Glu Gln Gly Ser		800
	805	810
Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met Ala Asp Leu Gly		815
	820	825
Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln Leu Val Tyr Gly		830
	835	840
Leu Asn Ala Leu Leu Ile Cys Val Gly Val Cys Ser Ser Gly Ile		845
	850	855
Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu His Asn Lys Leu		860
	865	870
Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro		875
	880	885
	890	895

900										905										910										
Ile	Gly	Arg	Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	Glu	Gln	Leu	Asp															
915										920										925										
Gln	Leu	Leu	Pro	Ile	Phe	Ser	Glu	Gln	Phe	Leu	Val	Leu	Ser	Leu	Met															
930										935										940										
Val	Ile	Ala	Val	Leu	Leu	Ile	Val	Ser	Val	Leu	Ser	Pro	Tyr	Ile	Leu															
945										950										955										
Leu	Met	Gly	Ala	Ile	Ile	Met	Val	Ile	Cys	Phe	Ile	Tyr	Tyr	Met	Met															
965										970										975										
Phe	Lys	Lys	Ala	Ile	Gly	Val	Phe	Lys	Arg	Leu	Glu	Asn	Tyr	Ser	Arg															
980										985										990										
Ser	Pro	Leu	Phe	Ser	His	Ile	Leu	Asn	Ser	Leu	Gln	Gly	Leu	Ser	Ser															
995										1000										1005										
Ile	His	Val	Tyr	Gly	Lys	Thr	Glu	Asp	Phe	Ile	Ser	Gln	Phe	Lys	Arg															
1010										1015										1020										
Leu	Thr	Asp	Ala	Gln	Asn	Asn	Tyr	Leu	Leu	Leu	Phe	Leu	Ser	Ser	Thr															
1025										1030										1035										
Arg	Trp	Met	Ala	Leu	Arg	Leu	Glu	Ile	Met	Thr	Asn	Leu	Val	Thr	Leu															
1045										1050										1055										
Ala	Val	Ala	Leu	Phe	Val	Ala	Phe	Gly	Ile	Ser	Ser	Thr	Pro	Tyr	Ser															
1060										1065										1070										
Phe	Lys	Val	Met	Ala	Val	Asn	Ile	Val	Leu	Gln	Leu	Ala	Ser	Ser	Phe															
1075										1080										1085										
Gln	Ala	Thr	Ala	Arg	Ile	Gly	Leu	Glu	Thr	Glu	Ala	Gln	Phe	Thr	Ala															
1090										1095										1100										
Val	Glu	Arg	Ile	Leu	Gln	Tyr	Met	Lys	Met	Cys	Val	Ser	Glu	Ala	Pro															
1105										1110										1115										
Leu	His	Met	Glu	Gly	Thr	Ser	Cys	Pro	Gln	Gly	Trp	Pro	Gln	His	Gly															
1125										1130										1135										
Glu	Ile	Ile	Phe	Gln	Asp	Tyr	His	Met	Lys	Tyr	Arg	Asp	Asn	Thr	Pro															
1140										1145										1150										
Thr	Val	Leu	His	Gly	Ile	Asn	Leu	Thr	Ile	Arg	Gly	His	Glu	Val	Val															
1155										1160										1165										
Gly	Ile	Val	Gly	Arg	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Gly	Met	Ala															
1170										1175										1180										
Leu	Phe	Arg	Leu	Val	Glu	Pro	Met	Ala	Gly	Arg	Ile	Leu	Ile	Asp	Gly															
1185										1190										1195										
Val	Asp	Ile	Cys	Ser	Ile	Gly	Leu	Glu	Asp	Leu	Arg	Ser	Lys	Leu	Ser															
1205										1210										1215										
Val	Ile	Pro	Gln	Asp	Pro	Val	Leu	Leu	Ser	Gly	Thr	Ile	Arg	Phe	Asn															
1220										1225										1230										
Leu	Asp	Pro	Phe	Asp	Arg	His	Thr	Asp	Gln	Gln	Ile	Trp	Asp	Ala	Leu															
1235										1240										1245										
Glu	Arg	Thr	Phe	Leu	Thr	Lys	Ala	Ile	Ser	Lys	Phe	Pro	Lys	Lys	Leu															
1250										1255										1260										
His	Thr	Asp	Val	Val	Glu	Asn	Gly	Gly	Asn	Phe	Ser	Val	Gly	Glu	Arg															
1265										1270										1275										
Gln	Leu	Leu	Cys	Ile	Ala	Arg	Ala	Val	Leu	Arg	Asn	Ser	Lys	Ile	Ile															
1285										1290										1295										
Leu	Ile	Asp	Glu	Ala	Thr	Ala	Ser	Ile	Asp	Met	Glu	Thr	Asp	Thr	Leu															
1300										1305										1310										
Ile	Gln	Arg	Thr	Ile	Arg	Glu	Ala	Phe	Gln	Gly	Cys	Thr	Val	Leu	Val															
1315										1320										1325										
Ile	Ala	His	Arg	Val	Thr	Thr	Val	Leu	Asn	Cys	Asp	His	Ile	Leu	Val															
1330										1335										1340										
Met	Gly	Asn	Gly	Lys	Val	Val	Glu	Phe	Asp	Arg	Pro	Glu	Val	Leu	Arg															

1345 1350 1355 1360
 Lys Lys Pro Gly Ser Leu Phe Ala Ala Leu Met Ala Thr Ala Thr Ser
 1365 1370 1375
 Ser Leu Arg

<210> 19
 <211> 2448
 <212> DNA
 <213> homo sapiens

<400> 19
 atgactagga agaggacata ctgggtgccc aactcttctg gtggcctcgt gaatcgtggc 60
 atcgacatag gcgatgacat ggttttcagga cttatttata aaacctatac tctccaagat 120
 ggcacctgga gtcagcaaga gagaatccct gaggcctccag ggaggccagc tgtcccaccg 180
 tgggggaagt atgatgctgc cttgagaacc atgattccct tccgtcccaa gccgaggttt 240
 cctgcccccc agccccctga caatgctggc ctgttctcct acctcacctg gtcactggctc 300
 accccgctca tgcaccaaag cttaccggagt cgttagatag agaaccacct cctccactg 360
 tcagtcctat atgcctcaga caaaaaatgct caaaggcttc accgcctttg ggaagaagaa 420
 gtctcaaggc gagggattga aaaaagcttca gtgcttctgg tgatgctgag gttccagaga 480
 acaaggttga ttttcgatgc acttctgggc atctgctctt gcattgccag tgactcggg 540
 ccaattattga ttataccaaa gatcctggaa tattcagaag agcagttggg gaatgtttgc 600
 catggagtgg gactctgctt tgcccctttt ctctccgaat gtgtgaagtc tctgagtttc 660
 tctccagttt ggcacatcaa ccaacgcaca gccatcaggt tccaaagcagc tgtttctctc 720
 tttgcctttg agaagctcat ccaatttaag ctgttaatac acatcacctc agggagaggcc 780
 atcagctctct tcaccggtga tgtaaactac ctgttttgaag ggggtgtgcta tggaccacctc 840
 gtactgacta cctgcgcata cgtggtcctc tgcagcattt ctctcactt cattatttga 900
 tacactgcat ttatttgcct cttatgctat ctctggtttt tcccaactgga ggtattcatg 960
 acaagaattg ctgtgaaggc tcagcatcac acatctgagg tcacggacca gccatccgt 1020
 gtgaccagtg aagtctctac ttcgattaa gctgattaaa tgtacacatg ggagaaacca 1080
 tttgcaaaaa tcatttgaaga cctaagaagg aaggaaaagga agctatttga gaagtgcggg 1140
 cttgtccaga gcttgacaag tataaccttg ttcatcatcc ccacagtggc cacagcggtc 1200
 tgggtttctca tccacacatc cttaaagctg aaactcacag cgtcaatggc ctccagcagt 1260
 ctggcctcct tgaatctctc tcggctgtca gtgttctttg tgcctattgc agtcaaaagt 1320
 ctacgaattt ccaagtctgc agtgatgagg ttcaagaagt ttttctcca ggagagccct 1380
 gttttctatg tcacagacc acaagacccc agcaaaagctc tgggtcttga ggaggccacc 1440
 ttgtctatggc aacagacctg tcccgggatc gtcaattggg cactggagct ggagaggaaac 1500
 gggcatgctt ctgaggggat gaccaggcct agagatgccc tcggggccaga ggaagaaggg 1560
 aacagccttg gccacagatt gcacaagatc aaacctgggtg tgtccaaggg gatgatgtta 1620
 ggggtctgcy gcaaacacggg gagtgtgaag agcagcctgt tgtcagccat cctggaggag 1680
 atgcaattgc tcgagggctc ggtgggggtg cagggaagcc tggcctatgt cccccagcag 1740
 gcctggatcg tcagcgggaa catcaggggag aacatcceta tgggaggcgc atatgacaag 1800
 gcccgatacc tccagtgct ccactgctgc tccctgaatc ggggaactga actctctccc 1860
 tttggagaca tgacagagat tggagagcgg ggcctcaacc tctctggggg gcagaaacag 1920
 aggatcagcc tggcccgccg cgtctattcc gaccgtcaga tctacctgct ggacgacccc 1980
 ctgtctgttg tggacggcca cgtggggaag cacatttttg aggagtgcat taagaagaca 2040
 ctacggggga agacggtgct cctggtgacc caccagctgc agtacttaga attttgtggc 2100
 cagatcattt tgttgaaaaa tgggaaaaat tgtgaaaatg gaactcacag tgaatttaatg 2160
 cagaaaaaag ggaatatgct ccaacttate cagaagatgc acaagggaagc cacttcggtt 2220
 ttcgctgccc ccatgagttt ctttgacacc atccccatag gccggctttt gaactgcttc 2280
 gcaggggcat tggaaacagct ggaccagctc ttgcccatct ttcacagaca gttcctggte 2340
 ctgtctctaa tggatgacgc cgtctctgtg attgtcagtg tgcgtctctc atatatcctg 2400
 ttaatgggag ccaataatcat ggttatttgc ttcatttatt atatgtga 2448

<210> 20
 <211> 812

<212> PRT

<213> homo sapiens

<400> 20

Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu
1 5 10 15
Val Asn Arg Gly Ile Asp Ile Gly Asp Met Val Ser Gly Leu Ile
20 25 30
Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg
35 40 45
Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Trp Gly Lys Tyr
50 55 60
Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe
65 70 75 80
Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp
85 90 95
Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn
100 105 110
Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln
115 120 125
Arg Leu His Arg Leu Trp Glu Glu Val Ser Arg Arg Gly Ile Glu
130 135 140
Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu
145 150 155 160
Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu
165 170 175
Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln
180 185 190
Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu
195 200 205
Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn
210 215 220
Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe
225 230 235 240
Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu
245 250 255
Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val
260 265 270
Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys
275 280 285
Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile
290 295 300
Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met
305 310 315 320
Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile
325 330 335
Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr
340 345 350
Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys
355 360 365
Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser
370 375 380
Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu
385 390 395 400
Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser
405 410 415

Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro
 420 425 430
 Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe
 435 440 445
 Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu
 450 455 460
 Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp
 465 470 475 480
 Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg
 485 490 495
 Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly
 500 505 510
 Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn
 515 520 525
 Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly
 530 535 540
 Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu
 545 550 555 560
 Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln
 565 570 575
 Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly
 580 585 590
 Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser
 595 600 605
 Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile
 610 615 620
 Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser
 625 630 635 640
 Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp
 645 650 655
 Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu
 660 665 670
 Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His
 675 680 685
 Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn
 690 695 700
 Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys
 705 710 715 720
 Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser
 725 730 735
 Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro Ile Gly Arg
 740 745 750
 Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp Gln Leu Leu
 755 760 765
 Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met Val Ile Ala
 770 775 780
 Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu Leu Met Gly
 785 790 795 800
 Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met
 805 810

<210> 21
 <211> 2586
 <212> DNA
 <213> homo sapiens

<400> 21

atgactagga	agaggacata	ctgggtgccc	aactcttctg	gtggcctcgt	gaatcgtggc	60
atcgacatag	gcgatgacat	ggtttcagga	cttatttata	aaacctatac	tctccaagat	120
ggccccctgga	gtcagcaaga	gagaaatcct	gaggctccag	ggaggggcagc	tgtccccaccg	180
tgggggaagt	atgatgtctg	cttgagaacc	atgatctcc	tccgtcccaa	cccgaggttt	240
cctgcccccc	agccccctgga	caatgctggc	ctgttctcct	acctcacogt	gtcatggtctc	300
accccgtcta	tgatccaaag	cttacggagt	cgcttagatg	agaacacccat	ccctccactg	360
tcagtccatg	atgcctcaga	caaaaatgtc	caaaggcttc	accgcctttg	gtgagaagaa	420
gtctcaaggc	gagggattga	aaaagcttca	gtgcttctgg	tgatgctgag	gttccagagca	480
acaagggtga	ttttcgtctg	acttctgggc	atctgcttct	gcaattgccag	gtctaggttg	540
ccaatatgta	ttataccaaa	gatcctggaa	tattcagaag	agcagttggg	gaatgtgtgc	600
catggagtgg	gaactctgct	tgcccttttt	cttccgaat	gtgtgaagtc	tctgagtttc	660
tcctccagtt	ggatcatcaa	ccaacgcaca	gcatcagggt	tccaagcage	tgtttctctc	720
tttgcccttg	agaagctcat	ccaatttaag	tctgtaatac	acatcacctc	aggagagccc	780
atcagcttct	tcaccggtga	tgtaaacctac	ctgtttgaag	gggtgtgcta	tggaccccta	840
gtactgtaca	cctgctgcat	gctggtctac	tcgacgattt	cttctcactt	cattattgga	900
tacactgcat	ttattgcat	cttatgctat	ctcctgtttt	tcccactgga	ggattattcat	960
acaagaattg	ctgtgaaggc	tcagcatcac	acatctgagg	tcagcgacca	gcgcattccgt	1020
gtgaccagtg	aagttctcac	ttgcatatag	ctgattaaaa	tgtaacacat	ggagaaacca	1080
tttgcacaaa	tcattgaaga	cctaagaagg	aaggaaagga	agctatttga	gaagtgcggg	1140
ctgtctcaga	gcctgacaag	tataaccttg	ttcatcatcc	ccacagtggt	cacagcggtc	1200
tgggttctca	tcacacatct	cttaaaagctg	aaactcacag	cgtaaatggc	cttcagcattg	1260
ctggcctcct	tgaatctcct	tcgggtgtca	gtgttctttg	tgccatttgc	agtcaaaagt	1320
ctcacgaatt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctctca	ggagagccct	1380
gttttctatg	tcacagcatt	acaagacccc	agcaaaagctc	tggtctttga	ggagaccacc	1440
ttgtcatggc	aacagaccctg	tcocggggatc	gtcaatgggg	cactggagct	ggagaggaa	1500
gggcatgctt	ctgaggggat	gaccagggct	agagatgcct	tcggggcaga	ggaagaaggg	1560
aacagcctgg	gccagagatt	gcacaagatc	aaactgtggg	tgctcaaggg	gatgatgtta	1620
ggggtctg	gcacaacggg	gagtggtaag	agcagcctgt	tgctcagcat	cctggaggag	1680
atgcacttgc	tcgagggctc	gggtgggggtg	caggggaagc	tgccctatgt	ccccagcag	1740
gcctggatgc	tcagcgggaa	catcaggggag	aaactctcca	tgggaggcgc	atatgacaa	1800
gcgcgatacc	tcagggtgct	ccactgtctg	tccttgaaat	gggaccttga	acttctgcc	1860
tttgagaca	tgacagagat	tgagagcggg	ggcctcaacc	ttctgtgggg	gcagaaacag	1920
aggatcagc	tggcccgccg	cgctctatcc	gaccgtcaga	ttacactgct	ggacgacccc	1980
ctgtctgctg	tggacgcccc	cggtggggaag	cacatttttg	aggagtgcac	taagaagaca	2040
ctcaggggga	agacggtcgt	cctgtgtgacc	caccagctgc	agtaactaga	atttgtgtgc	2100
cagatcattt	gtgtgaaaaa	tgtgaaaaat	tgtgaaaaat	gaactcacag	tgagttaatg	2160
cagaaaaagt	ggaaatatgc	ccaacttctc	cagaagaatgc	acaagggaagc	cacttcggtt	2220
ttccgctgcc	ccatgagttt	ctttgacacc	atcccaatag	gccggtcttt	gaactgtctc	2280
gcaggggact	tggaaacagct	ggaccagctc	ttgcccatct	tttcagagca	gttctgtgtc	2340
ctgtccttaa	tggtgatcgc	cgctctgttg	attgtcagtg	tgctgtctcc	atatatctgt	2400
ttaatgggag	ccataatcat	gggttatgtc	ttcatttatt	atatgatgtt	caagaagccc	2460
atcgggtgtg	tcaagagact	ggagaactat	agccggtctc	ctttattctc	ccacatctcc	2520
aattctctgc	aaggcctgag	ctccatccat	gtctatggaa	aaactgaaga	cttcacagc	2580
cagtgga						2586

<210> 22
 <211> 858
 <212> PRT
 <213> homo sapiens

<400> 22

Met	Thr	Arg	Lys	Arg	Thr	Tyr	Trp	Val	Pro	Asn	Ser	Ser	Gly	Leu
1				5				10					15	
Val	Asn	Arg	Gly	Ile	Asp	Ile	Gly	Asp	Met	Val	Ser	Gly	Leu	Ile
			20				25				30			

Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg
 35 40 45
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr
 50 55 60
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe
 65 70 75 80
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp
 85 90 95
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn
 100 105 110
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln
 115 120 125
 Arg Leu His Arg Leu Trp Glu Glu Glu Val Ser Arg Arg Gly Ile Glu
 130 135 140
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu
 145 150 155 160
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu
 165 170 175
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Gly Glu Gln
 180 185 190
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu
 195 200 205
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn
 210 215 220
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe
 225 230 235 240
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu
 245 250 255
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val
 260 265 270
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys
 275 280 285
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile
 290 295 300
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met
 305 310 315 320
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile
 325 330 335
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr
 340 345 350
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys
 355 360 365
 Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser
 370 375 380
 Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu
 385 390 395 400
 Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser
 405 410 415
 Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro
 420 425 430
 Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe
 435 440 445
 Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu
 450 455 460
 Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp
 465 470 475 480

Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg
 485 490 495
 Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly
 500 505 510
 Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn
 515 520 525
 Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly
 530 535 540
 Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu
 545 550 555 560
 Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln
 565 570 575
 Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly
 580 585 590
 Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser
 595 600 605
 Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile
 610 615 620
 Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser
 625 630 635 640
 Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp
 645 650 655
 Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu
 660 665 670
 Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His
 675 680 685
 Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn
 690 695 700
 Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys
 705 710 715 720
 Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser
 725 730 735
 Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro Ile Gly Arg
 740 745 750
 Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp Gln Leu Leu
 755 760 765
 Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met Val Ile Ala
 770 775 780
 Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu Leu Met Gly
 785 790 795 800
 Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met Met Phe Lys Lys
 805 810 815
 Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser Arg Ser Pro Leu
 820 825 830
 Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser Ser Ile His Val
 835 840 845
 Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln
 850 855

<210> 23
 <211> 3660
 <212> DNA
 <213> homo sapiens

<400> 23
 atgactagga agaggacata ctgggtgccc aactcttctg gtggcctcgt gaatcgtagg

60

atcgacatag	gcgatgacat	ggtttcaggga	cttatttata	aaacctatac	tctccaagat	120
ggccctggga	gtcagcaaga	gagaaatcct	gagggtccag	ggaggggcagc	tgtcccacgc	180
tgggggaagt	atgatgtctg	cttgagaacc	atgatccct	tccgtcccaa	gccgaggttt	240
cctgcccccc	agccctggga	caatgctggc	ctgttctcct	acctcacgct	gtcatggctc	300
accctgccta	tgatccaaag	cttacggagt	cgcttagatg	agaacacatc	ccctccactg	360
tcagtccatg	atgcctcaga	caaaaatgtc	caaaggcttc	accgcctttg	ggaagaagaa	420
gtctcaaggc	gagggttca	aaaagcttca	gtgcttctgg	tgatgctgag	gttccagaga	480
acaaggttga	ttttcgatgc	acttctgggc	atctgcttct	gcattgccag	tgtactcggg	540
ccaatatgga	ttataccaaa	gatcctggaa	tattcagaag	agcagttggg	gaatgttgtc	600
catggagttg	gactctgctt	tgcccttttt	ctctccgaat	gtgtgaagct	cttgagtttc	660
tctctcagtt	ggaatcatca	ccaacgcaca	gccatcaggt	tccaagcagc	tgtttctccc	720
ttgtcctttg	agaagctcac	ccaatttaag	tcgttaatac	acatacctc	aggagagggc	780
atcagctctt	tcaccggtga	tgtaaacatc	ctgtttgaag	gggtgtgcta	tggaccctta	840
gtactgatca	cctgcgcata	gctgggtcat	tgcagcatct	cttctcactt	cattatttga	900
tcacactgat	ttattggcat	cttatgctat	ctcctggttt	tcccactgga	ggatattcatg	960
acaagaattg	ctgtgaaggc	tcagcatcac	acatctgagg	tcagcgacca	ggcatccctg	1020
gtgacaggtg	aagtctctac	ttgcattaag	ctgattaaaa	tgtcacatgt	cgagaaacca	1080
tttgcaaaaa	tcattgaaga	cctaagaagg	aaggaaagga	agctatttga	gaagtgcggg	1140
cttgtccaga	gcctgacaa	tataaccttg	tctcatctcc	ccacagtggc	cacagcggtc	1200
tgggtttctc	tcacacatc	cttaaaagctg	aaactcacag	cgctcaatggc	cttcagcgtc	1260
ctggcctcct	tgaatctcct	tcgggtgtca	gtgttctttg	tgccatttgc	agtcacaaagt	1320
ctcacgaatt	ccaagctctg	agtgatgagg	ttcaagaagt	ttttctccca	ggtagcgccct	1380
gttttctatg	tcacagcatt	acaagacccc	agcaaaagctc	tggtctttga	ggaggccacc	1440
ttgtcatggc	aacagacctg	tcccgggata	gtcaatgggg	cactggagct	ggagaggaac	1500
gggcatgctt	ctgaggggat	gaccaggcct	agagatgccc	tccgggacaga	ggagaagagg	1560
aacagccttg	gccacagatt	gcacaagatc	aacctgggtg	tgtccaagtg	gatgacgtta	1620
ggggctctgg	gcacaacggt	gagtggttaag	acagcgcctg	tgtcagccat	cctgaggagg	1680
atgactctgc	tcgagggctc	gggtgggggtg	cagggaaagcc	tggcctatgt	ccccagcag	1740
gctcgatgac	tcagcggtgc	catcagggaag	aaactctcca	tgggagggcg	atatgacaag	1800
gcccgatacc	tcagggtgct	ccactgctgc	tcctgaatc	gggacctgga	acttctgccc	1860
tttgagacca	tgacagagat	tggagagcgg	ggcctcaacc	tctctggggg	gcagaacaacg	1920
aggatcagcc	tggcccgctg	cgctatttcc	gaccgtcaga	tctacctgat	ggacgacccc	1980
ctgtctgctg	tggacgcccc	cgtgggggaag	cacatttttg	aggagtgcac	taagaagaca	2040
ctcagggggg	agacgggtgc	ctgggtgacc	caccagctgc	agactttaga	attttgtggc	2100
cagatcattt	tggtggaaaa	tgggaaaaatc	tgtgaaaatg	gaactcacag	tgagttaatg	2160
cagaaaaaag	ggaaaatagc	ccaacttacc	acagaagatg	acaaggaagc	cacttctggt	2220
ttccgctgcc	ccatgagttt	ctttgacacc	atcccaatag	gcgggctttt	gaactgcttc	2280
gcaggggctt	tggaaacagct	ggaccagctc	ttgcccatct	tttcagagca	gttcttgctc	2340
ctgtctctaa	tgggtgatgc	cgctcctgtt	attgtcaagt	tgtgtctccc	atatactcgt	2400
ttaatgggag	ccataatcat	ggttatttgc	ttcatttatt	atatgatgtt	caagaaggcc	2460
atcgggtgtg	tcaagagact	ggagaactat	agccggtctc	ctttattctc	ccacatcttc	2520
aattctctgc	aaggcctgag	ctccatccat	gtctatggaa	aaactgaaga	cttcatcagc	2580
cagtttaaga	ggctgactga	tgcgcagaa	aactacctgc	tgttgtttct	atcttccaca	2640
cgatggagtg	cataggcctg	ggagatcatg	accaaccttg	tgaccttgge	tgttgccctg	2700
ttcgtggctt	ttggcatttc	ctccaccccc	tactccttta	aagtcatggc	tgtcaaacatc	2760
ctgctcagcg	tggcgtccag	cttcaggccc	actgcocgga	tggcgttggg	gcagagagca	2820
cagtttcacg	ctgtagagag	gatactgcag	tacatgaaga	tgtgtgtctc	ggaagctcct	2880
ttacacatgg	aaggcacaag	ttgtccccag	gggtggccac	agcatggggg	aatcatattt	2940
caggattatc	acatgaataa	cagagacaac	acaccccacg	tgcttcacgg	cactcaacctg	3000
accatccogc	gccacggaat	gggtgggcatc	gtgggaagga	cgggctctgg	gaagtctctc	3060
ttgggcatct	ctctctcccg	ctcgttgagg	ctcatggcag	ccgggattct	cattgacgcg	3120
gtggacattt	gcagcatcgg	cctggaggac	ttgcggtcca	agctctcagt	gatccctcaa	3180
cagtgatgct	tgctctcagc	aaacctcaga	ttcaacctag	atcccttga	cgctcacact	3240
gaccagcaga	tctgggatgc	cttggagagg	acattctctga	ccaaggccat	ctcaaaagttc	3300
cccaaaaagc	tgctacaga	tgtggtggaa	aacgggtgaa	acttctctgt	gggggagagg	3360
cagctgctct	gcattgccag	ggctgtgctt	cgcaactcca	agatcatcct	gtcagatgaa	3420

gcccagcgcct ccattgacat ggagacagac accctgatcc agcgacacat cgtgaagcc 3480
 ttccagggtc gcaccgtgct cgtcattgcc caccgtgtca ccactgtgct gaactgtgac 3540
 cacatctcgt ttatgggcaa tgggaagggt gtagaatttg atcgcccgga ggtactgcgg 3600
 aagaagcctg ggtcattggt cgcagccctc atggccacag ccacttcttc actgagataa 3660

<210> 24

<211> 1216

<212> PRT

<213> homo sapiens

<400> 24

Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu
 1 5 10 15
 Val Asn Arg Gly Ile Asp Ile Gly Asp Asp Met Val Ser Gly Leu Ile
 20 25 30
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg
 35 40 45
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr
 50 55 60
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe
 65 70 75 80
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp
 85 90 95
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn
 100 105 110
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln
 115 120 125
 Arg Leu His Arg Leu Trp Glu Glu Glu Val Ser Arg Arg Gly Ile Glu
 130 135 140
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu
 145 150 155 160
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu
 165 170 175
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Gly Gln
 180 185 190
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu
 195 200 205
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn
 210 215 220
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe
 225 230 235 240
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu
 245 250 255
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val
 260 265 270
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys
 275 280 285
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile
 290 295 300
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met
 305 310 315 320
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile
 325 330 335
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr
 340 345 350
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys

355										360										365									
Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln	Ser	Leu	Thr	Ser														
370							375				380																		
Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala	Val	Trp	Val	Leu														
385						390					395				400														
Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser	Met	Ala	Phe	Ser														
				405					410					415															
Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val	Phe	Phe	Val	Pro														
			420					425					430																
Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala	Val	Met	Arg	Phe														
			435					440					445																
Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr	Val	Gln	Thr	Leu														
			450			455					460																		
Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala	Thr	Leu	Ser	Trp														
465						470				475					480														
Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu	Glu	Leu	Glu	Arg														
				485					490					495															
Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg	Asp	Ala	Leu	Gly														
			500					505					510																
Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu	His	Lys	Ile	Asn														
			515				520					525																	
Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys	Gly	Asn	Thr	Gly														
			530			535					540																		
Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu	Glu	Met	His	Leu														
545						550				555					560														
Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala	Tyr	Val	Pro	Gln														
				565					570				575																
Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn	Ile	Leu	Met	Gly														
			580				585						590																
Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu	His	Cys	Cys	Ser														
			595				600					605																	
Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp	Met	Thr	Glu	Ile														
			610				615					620																	
Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ser														
625						630				635					640														
Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr	Leu	Leu	Asp	Asp														
				645					650				655																
Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His	Ile	Phe	Glu	Glu														
			660				665						670																
Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val	Leu	Val	Thr	His														
			675				680						685																
Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile	Leu	Leu	Glu	Asn														
			690				695					700																	
Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu	Met	Gln	Lys	Lys														
705						710				715					720														
Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys	Glu	Ala	Thr	Ser														
				725					730				735																
Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	Asp	Thr	Ile	Pro	Ile	Gly	Arg														
			740						745				750																
Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	Glu	Gln	Leu	Asp	Gln	Leu	Leu														
			755				760					765																	
Pro	Ile	Phe	Ser	Glu	Gln	Phe	Leu	Val	Leu	Ser	Leu	Met	Val	Ile	Ala														
			770				775					780																	
Val	Leu	Leu	Ile	Val	Ser	Val	Leu	Ser	Pro	Tyr	Ile	Leu	Leu	Met	Gly														
785						790				795					800														
Ala	Ile	Ile	Met	Val	Ile	Cys	Phe	Ile	Tyr	Tyr	Met	Met	Phe	Lys	Lys														

<400> 25

agagacagga	acagagcccc	tcatctcacc	tctgggctac	catacagaaa	agcaggtgta	60
tttgaataaa	ccaggttggc	aaatcatact	atagctgaaa	gaattggcag	gaactgaaaa	120
tgcatagaaa	gaggacatac	tgggtgccca	actcttctgg	tgccctcgtg	aatcgtggca	180
tcgacatagg	cgatgacatg	gtttcaggac	ttatttataa	aaactatact	ctccaagatg	240
gccctcggag	tcagcaagag	agaaatcctg	aggctccagg	gagggcagct	gtcccaccgt	300
gggggaagta	tgatgctgoc	ttgagaacca	tgattccctt	cgttcccaag	ccgaggtttc	360
ctgcccccca	gcccctggac	aatgctggcg	tgttctccta	cctcaccgtg	tcattggctca	420
cccgcgtcat	gataccaaagc	ttacggagtc	gcttagatga	gaacaccatc	cctccactgt	480
cagtcacatg	tgcttcacagc	aaaaatgtcc	aaaggcttca	ccgcttttgg	gaaggaagtg	540
tctcaaggcg	agggatgtaaa	aaagcttcag	tgcttctggt	gatgctgagg	ttccagagaa	600
caaggcttga	ttctgatgca	ctctcgggca	tctgtctctg	cattgccagt	gtactcgggc	660
cagactgcac	caatggggga	ggtgggagtc	ttcccagaag	aaaactgagg	cactgggtacc	720
agctacgggg	aggtgaagat	attgattata	ccaaagatcc	tggaatatcc	agaagagcag	780
ttgggggaatg	ttgtccatgg	agtgggactc	tgctttggcc	ttttctctct	cgaatgtgtg	840
aagtctctga	gtttctctct	cagttgggac	atcaaccaac	gcacagccat	caggttccaa	900
gcagctgttt	cctctcttgc	ctttgagaag	ctcatccaat	ttaagcttgt	aatcacatc	960
agctcaggag	aggccatcag	cttcttcacc	ggtgatgtaa	actacctgtt	tgaaggggtg	1020
tgctatggac	ccctagtact	gatcacctgc	gcactcgtgg	tcactctgcg	cattttctcc	1080
tacttctatta	ttggatacac	tgcatattat	gccattctat	gctatctcct	ggttttccca	1140
ctggaggttat	tcattgacaa	aatggctgtg	aaggctcagc	atcacacatc	tgagggtcag	1200
gaccacggca	tcctgtgtgc	cagtgaaagt	ctcaactgtca	taagcttgat	taaaagtac	1260
acatggggaga	aaccatttgc	aaaaatcatt	gaagacctaa	gaaggaagga	aaggaagcta	1320
ttgggaaggt	gcgggcttgt	ccagagcctg	acaagtataa	ccttgttcat	catccccaac	1380
gtggccacag	cgggtctggg	tctcatccac	acatccttaa	agctgaaact	cacagcgta	1440
atggccttca	gcatgctggc	ctccttgaat	ctccttcggc	tgctcagttg	ctttgtgcct	1500
attgcagtc	aaagtctcac	gaattccaa	ttctcagtg	tgaggttcaa	gaagtttttc	1560
ctccaggaga	gcctcttttt	ctatgtccag	acattcaaac	accccagcaa	agctctggct	1620
tttggaggag	ccacctgttc	atggcaaac	acactgtccc	ggatcgtcaa	tgggggcactg	1680
gagctggaga	ggaacgggca	tgctctctag	gggatgcaca	ggcctagaga	tgccctcggg	1740
ccagaggaag	aagggaacag	cctggggcca	gagttgcaca	agatcaacct	gggtggtgtcc	1800
aaggggatga	tgtttagggg	ctgcggcaac	acggggagtg	gtaagagcag	ctgtgtgtca	1860
gccatctctg	aggagatgca	cttgctccag	ggctcgggtg	gggtgcaggg	aagcctggcc	1920
tatgtccccc	agcaggcctg	gatcgtccag	gggaacatca	gggagaacat	cactctggga	1980
ggcccatatg	acaaggcccg	atacctccag	gtgctccaat	gctgctccct	gaatcgggag	2040
ctggaaactc	tgcccttttg	agacatgaca	gagattggag	agcgggggct	caacctctct	2100
ggggggcaga	aacagaggat	cagcctggcc	cgcccgctct	attccgaccg	tcagatctac	2160
ctgctggagc	acccctctgt	tgcttgggac	gcccaactgg	ggaagcacat	ttttgagtag	2220
tgcatataa	agacactcag	ggggaagacg	tgctgtctgg	tgacccaaca	gctgcagtag	2280
ttagaatttt	gtggccagat	cattttgttg	gaaaatggga	aaatctgtga	aaatgggaact	2340
ccagctgagt	taatgcagaa	aaaggggaaa	tatgcccac	ttatccagaa	gatgcacaa	2400
gaagccactt	cggacatgtt	gcaggacaca	gcaaagatag	cagagaagcc	aaaggtagaa	2460
agtacaggct	tgggccacct	cctggaagag	tctctcaacg	gaaatgctgt	gcggagacat	2520
cagctcacac	aggaggagga	gatggaagaa	ggctccttga	gttggagggt	ctaccaacct	2580
tacatccagg	cagctggagg	ttacatggtc	tcttgcataa	ttttctctct	cggtgtgtgt	2640
atcgtctctt	taacagatct	cagcttctgg	tggtcagct	actggttgga	gcagggtcgt	2700
gggaccaata	gcagccgaga	gagcaatgga	accatggcag	acctgggcaa	cattgcagac	2760
aatcctcaac	tgctcttcta	ccagctgggt	tacgggtcca	acgcccctgt	cctcatctgt	2820
gtgggggtct	gctcctcagg	gattttcacc	aaggtcacga	ggaaggcact	cacggccctg	2880
cacaaacagg	tcttcaacaa	ggttttccgc	tgccccatga	gtttcttttg	caccatccca	2940
ataggccgct	ttttgaactg	cttgcagggg	gaacttggaa	agctggacca	gctcttggcc	3000
atcttctctg	agcagttctc	ggtcctgtcc	ttaatggtga	tcgcgctctc	gttgattgtc	3060
agtgctgtgt	ctccatatat	cctgtttaat	ggagccataa	tcattggttat	ttgcttcat	3120
tattatatgt	gagttaggttc	tttttgcctg	tgactttggg	agcaagggct	gggacaaacc	3180
cagactagat	ggtcccacag	gtggacggct	caggttccct	acctccactg	tcctatcgag	3240
atgtttcaaga	aggccatcgg	tggtttcaag	agactggaga	acctatagcg	ctctctttaa	3300

tctccca	tctcaattc	tctgcaaggc	ctgagctcca	tccatgtcta	tggaaaaact	3360
gaagacttca	tcagccagtg	agtccttctg	ctgccatttt	gagaatgatg	gaaccaccag	3420
gggtgggtgg	ggagccagg	aaagaatggg	acgtcttgag	agtggatcat	cttcaaaaag	3480
cattcagaga	gccacattgg	tcgattgaga	cgtattctct	gagccttcca	gaacctgtcg	3540
gaaccattct	ttcatttaag	aggctgactg	atgcgcagaa	taactacctg	ctgttgtttc	3600
tatcttccac	acgatggatg	gcattgaggc	tggagatcat	gaccaacctt	gtgaccttgg	3660
ctgttgccct	gttcgtggct	tttggcattt	cctccacccc	ctactccttt	aaagtcatgg	3720
ctgtcaacat	cgtgctgcag	ctggcgtcca	gcttccaggc	cactgcccg	attggcttgg	3780
agacagaggc	acagtccacg	gctgtagaga	ggatactgca	gtacatgaag	atgtgtgtct	3840
cggaaagctc	tttacacatg	gaaggcacia	gttgctccca	gggtgggcca	cagcatgggg	3900
aaatcatatt	tcaggattat	cacatgaat	acagagacaa	cacaccacc	gtcttccacg	3960
gcatacaact	gaccatccgc	ggccacgaag	tgtggggcat	cgtgggaagg	acgggctctg	4020
ggaagtccct	cttgggcatg	gctctcttcc	gcctgggtgga	gcccatggca	ggccggatcc	4080
tcattgacgg	cgtggacatt	tgccagcatcg	gcctggaggga	cttgcgggtcc	aaagctctcag	4140
tgatccctca	agatccagtg	ctgctctcag	gaaccatcag	attcaacctt	gatcccttgg	4200
accgtcacac	tgaccagcag	atctgggatg	ccttggagag	gacattctcg	accaaggcca	4260
tctcaaaagt	ccccaaaaag	ctgcatacag	atgtggtgga	aaacggtgga	aacttctctg	4320
tgggggagag	gcagctgctc	tgcatgtcca	gggctgtgct	tcgcaactcc	aaagatcatcc	4380
ttatcgatga	agccacagcc	tcatttgaca	tggagacaga	cacctgtatc	cagcgacaaa	4440
tccgtgaagc	cttccaggcc	tgccaccgtgc	tcgtcatg	ccaccgtgtc	accactgtgc	4500
tgaactgtga	ccacatctctg	gttatgggca	atgggaaggt	ggtagaattt	gatcgggcgg	4560
aggctactgc	gaagaagcct	gggtcattgt	tcgcagccct	catggccaca	gccacttctt	4620
cactgagata	aggagatgtg	gagacttcat	ggagctggc	agctgagctc	agaggttcac	4680
acaggtgcag	cttcgaggcc	cacagtctgc	gaccttctg	tttggagatg	agaacttctc	4740
ctggaagcag	gggtaaatgt	aggggggggtg	gggatttgctg	gatggaaacc	ctgggaatagg	4800
ctacttggatg	gctctcaaga	ccttagaacc	ccagaaccat	ctaagacatg	ggattcagtg	4860
atcatgtgtg	tctcttttta	acttacatgc	tgaataattt	tataataagg	taaaagctta	4920
tagtttctg	atctgtgtta	gaagtgttgc	aaatgctgta	ctgactttgt	aaaaataaaa	4980
actaaggaaa	actcaaaaaa	aaaaaaaaaa	aaaaaaaaaa			5020